methadone has been researched along with Hepatitis C in 231 studies
Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3)
methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.
6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.
Hepatitis C: INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hepatitis C virus (HCV) is a prevalent chronic blood-borne infection among opioid-dependent patients on methadone maintenance treatment (MMT)." | 9.16 | Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. ( Acosta, A; Altice, FL; Bruce, RD; Eiserman, J; Gote, C; Lim, JK, 2012) |
| "Most methadone-maintained injection drug users (IDUs) have been infected with hepatitis C virus (HCV), but few initiate HCV treatment." | 9.15 | Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. ( Arnsten, JH; Berg, KM; Hidalgo, J; Li, X; Litwin, AH, 2011) |
| "To examine the long-term impact of methadone maintenance treatment (MMT) on mortality, re-incarceration and hepatitis C seroconversion in imprisoned male heroin users." | 9.11 | Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. ( Dolan, KA; Kaldor, J; Shearer, J; White, B; Wodak, AD; Zhou, J, 2005) |
| "A prospective study was conducted on the evolution of serum transaminases in 116 patients infected with hepatitis C virus (HCV), parenteral drug abusers, included for 6 months in treatment programs with methadone, naltrexone or "drug free" regimen." | 9.08 | [Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection]. ( Gutiérrez Mora, E; Lozano Polo, JL; Martínez Pérez, V; Santamaría Gutiérrez, J; Vada Sánchez, J; Vallejo Correas, JA, 1997) |
| "Although hepatitis C virus (HCV) prevails in patients receiving methadone maintenance treatment (MMT), most do not receive anti-HCV therapy." | 8.12 | Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic. ( Chan, HW; Chang, TT; Changchien, TC; Chen, CC; Chen, TH; Huang, CK; Lin, PC; Sie, YT; Tai, CM; Tsai, CT; Tseng, CH; Wang, DW; Yen, YC; Yu, ML, 2022) |
| "There is a dearth of research on hepatitis C virus (HCV) treatment uptake among people who inject drugs (PWIDs) and receive methadone substitution treatment (MST) in Eastern Europe and Central Asia countries." | 8.02 | Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia. ( Gamkrelidze, A; Getia, V; Gvinjilia, L; Khonelidze, I; Kuchuloria, T; Stvilia, K; Tsereteli, M; Vephkvadze, N, 2021) |
| "Despite the efforts to curb viral hepatitis and HIV infections through Methadone clinics, infection rates among people who use drugs are still high and the general knowledge on preventive measures is inadequate." | 8.02 | Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study. ( Bakshi, FA; Gunda, DW; Jaka, H; Kalokola, F; Kilonzo, SB; Majinge, DC; Manyiri, PM; Mtui, G; Shao, ER; Stephano, A, 2021) |
| "People on methadone treatment have increased their life expectancy, aging prematurely with comorbidities." | 7.91 | [Aging in a methadone maintenance program. A perspective from the framework of social determinants of health]. ( Gutiérrez-Cáceres, S; Pedraz-Marcos, A; Serrano-Gallardo, P, 2019) |
| "We aimed to evaluate the status and barriers related to hepatitis C virus (HCV) treatment among Chinese methadone maintenance treatment (MMT) clients, and the willingness and barriers of patients to accept directly observed treatment (DOT) service and oral direct-acting antivirals (DAAs)." | 7.91 | Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study. ( Chen, W; Gong, C; Ling, L; Liu, Y; Zou, X, 2019) |
| "Despite high hepatitis C virus (HCV) prevalence, opioid use disorder (OUD) patients on methadone rarely engage in HCV treatment." | 7.91 | Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone. ( Andrews, P; Brown, LS; Chen, Y; Markatou, M; Mcleod, A; Sylvester, C; Talal, AH, 2019) |
| "The majority of patients undergoing methadone maintenance treatment (MMT) are neither examined nor treated for hepatitis C virus (HCV) infection." | 7.91 | Integrated care for methadone maintenance patients with hepatitis C virus infection. ( Bair, MJ; Chang, TT; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Tai, CM; Tseng, CH; Yeh, ML; Yen, YC; Yu, ML, 2019) |
| "To assess trends and related factors in HIV and/or hepatitis C virus (HCV) antibody testing and infection among injection drug users (IDUs) newly entering methadone maintenance treatment (MMT) in Guangdong Province, China." | 7.85 | Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study. ( Chen, W; Ling, L; Liu, Y; Zou, X, 2017) |
| "The aim of this study was to characterize the epidemiology and disease related to hepatitis C in a population attending a low-threshold methadone program." | 7.85 | Hepatitis C in a Mobile Low-Threshold Methadone Program. ( Água-Doce, I; Balsa, C; Belo, E; Coutinho, R; Lopes, P; Loureiro, R; Martins, HC; Pádua, E; Pereira, C; Silva, MJ, 2017) |
| "Methadone maintenance treatment patients in Wuhan, China show a high prevalence of hepatitis C virus at admission (72." | 7.81 | Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. ( Chawarski, MC; Desrosiers, A; Liu, M; Liu, P; Luo, L; Peng, J; Schottenfeld, R; Wang, X; Xie, N; Zhou, S; Zhou, W, 2015) |
| "This study explores the trends and associated factors of HIV, hepatitis C virus (HCV) and syphilis seroconversion among Chinese methadone maintenance treatment (MMT) clients over a follow-up period of up to 7 years." | 7.81 | Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort study. ( Ling, L; Zhang, L; Zou, X, 2015) |
| "To determine the relationship between methadone maintenance therapy (MMT) and hepatitis C (HCV) seroconversion among illicit drug users." | 7.80 | The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. ( Dias Lima, V; Fairbairn, N; Grebely, J; Kerr, T; Montaner, J; Nolan, S; Wood, E, 2014) |
| "This study investigates the prevalence and correlates of hepatitis C virus (HCV) infections among heroin dependent individuals who received methadone maintenance therapy in Taiwan." | 7.79 | High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan. ( Chang, TJ; Chen, VC; Chou, JY; Gossop, M; Lee, PC; Lin, TY; Ng, MH; Shao, WC, 2013) |
| "Depression and hepatitis C virus (HCV) infection are two common conditions among heroin users in methadone maintenance treatment (MMT)." | 7.79 | Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China. ( Du, J; Mandel, JS; Page, K; Wang, Z; Xiao, Z; Zhao, M, 2013) |
| "We used a 25-item, self-administered questionnaire to assess staff's perceived barriers and willingness to engage in onsite treatment of hepatitis C virus (HCV) at the Beth Israel Medical Center methadone maintenance treatment program (MMTP) at its Harlem sites." | 7.79 | Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. ( Des Jarlais, DC; Dimova, RB; Perlman, DC; Peterson, RH; Seewald, R; Talal, AH; Zeremski, M, 2013) |
| "This study aims to: (1) document the prevalence of hepatitis C virus (HCV) among methadone maintenance treatment (MMT) patients in Kunming and Shanghai; (2) examine risk factors for HCV by comparing those who tested positive with those who were negative and (3) examine if HCV serostatus is related to attitudes toward MMT." | 7.78 | Hepatitis C among methadone maintenance treatment patients in Shanghai and Kunming, China. ( Chang, YJ; Du, J; Evans, E; Hser, Y; Li, J; Peng, CY; Zhao, M, 2012) |
| "The aim was to investigate hepatitis C virus (HCV) knowledge and alcohol consumption among patients (n = 114) in a methadone maintenance treatment (MMT) clinic in Shanghai." | 7.78 | Hepatitis C knowledge and alcohol consumption among patients receiving methadone maintenance treatment in Shanghai, China. ( Du, J; Wang, Z; Xie, B; Zhao, M, 2012) |
| "To provide evidence for policy makers for human immunodeficiency virus (HIV) prevention and control, we investigated HIV, syphilis, and hepatitis C virus (HCV) infection and the availability of methadone maintenance treatment (MMT) among migrant drug users in Beijing." | 7.78 | High prevalence of HIV, syphilis and HCV, and low methadone maintenance treatment in a migrant population in Beijing. ( Cao, X; Chu, P; Jia, Z; Li, D; Li, S; Liu, Z; Lu, L; Ruan, Y; Yang, Y, 2012) |
| "To study the risk factors for seroconversion to hepatitis C virus (HCV) infection since admission to methadone maintenance treatment (MMT) and to characterize the seronegative admitted group." | 7.77 | Low risk for hepatitis C seroconversion in methadone maintenance treatment. ( Adelson, M; Peles, E; Rados, V; Schreiber, S, 2011) |
| "Hepatitis C virus (HCV) knowledge, attitudes, beliefs, and experiences (KABE) of 64 HCV antibody positive methadone maintenance treatment (MMT) patients were assessed in conjunction with acceptability of an on-site semi-structured HCV education session, HCV RNA diagnostic testing, HCV treatment motivational assessment, and initiation of HCV treatment." | 7.76 | Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. ( Batki, SL; Canfield, KM; Smyth, E, 2010) |
| " We report the case of a 50-year-old man with hepatitis C cirrhosis who demonstrated dramatic improvement in HPS after withdrawal from chronic methadone therapy." | 7.76 | Improvement in hepatopulmonary syndrome after methadone withdrawal: a case report with implications for disease mechanism. ( Lau, EM; McCaughan, G; Torzillo, PJ, 2010) |
| "To describe the patterns of screening for hepatitis C virus (HCV) infection in methadone-maintained pregnant women and their infants." | 7.75 | Screening for hepatitis C virus infection in methadone-maintained mothers and their infants. ( An, EI; Leroi, MJ; Liu, AJ; Murray, HG; Nanan, RK; Tetstall, E, 2009) |
| "The purpose of this article was to investigate the personal and social barriers experienced by methadone maintained clients when seeking treatment for alcohol abuse along with strategies for engaging such clients in treatment programs." | 7.74 | Alcohol use reduction program in methadone maintained individuals with hepatitis C virus infection. ( Cohen, A; de Castro, V; Khalilifard, F; Marfisee, M; McNeese-Smith, D; Nyamathi, A; Nyamathi, K; Shoptaw, S, 2008) |
| "We examined the impact of methadone maintenance treatment (MMT) on risk behaviors for transmission of blood-borne diseases in polydrug users who had tested positive or negative for hepatitis C virus (HCV)." | 7.74 | Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. ( Belendiuk, KA; Epstein, DH; Preston, KL; Schmittner, J; Willner-Reid, J, 2008) |
| "Despite the high prevalence of hepatitis C virus (HCV) infection among drug users enrolled in methadone maintenance treatment programs, few drug users are being treated with combination therapy." | 7.73 | Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. ( Gourevitch, MN; Litwin, AH; Soloway, I, 2005) |
| "The safety, efficacy, and tolerability of nelfinavir (NFV)-containing antiretroviral therapy were evaluated in patients coinfected with HIV and hepatitis C undergoing methadone maintenance at an urban outpatient opioid treatment program serving a minority adult population." | 7.73 | Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance. ( Brown, LS; Chu, M; Kritz, S; Madray, C, 2006) |
| "The survey of viral infections in the liver investigated by means of serological markers of hepatitis A, B and C in drug addicts on methadone maintenance treatment is important for the next procedures." | 7.72 | [Prevalence of serological markers of viral hepatitis B and hepatitis C in drug-dependent individuals treated at the Drop Methadone Center in Prague]. ( Urbánek, P; Wilczek, H, 2003) |
| " Hepatitis C virus (HCV) is highly prevalent among intravenous drug users (IDUs) and the 'offer' of a serological test for HCV antibodies is now seen as a national standard within drug misuse services, including GP methadone clinics." | 7.72 | Finding a vein or obtaining consent: a qualitative study of hepatitis C testing in GP methadone clinics. ( Chew-Graham, C; Perry, M, 2003) |
| "The cost-effectiveness of hepatitis C virus (HCV) anti-viral therapy for injecting drug users (IDUs) on methadone maintenance is important because the majority have chronic infections that remain untreated." | 7.72 | What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? ( Green, FT; Sellman, JD; Sheerin, IG, 2004) |
| "The prevalence of human immunodeficiency virus (HIV) infection and hepatitis B, C, and G virus infections was determined in a selected group of 40 intravenous drug addicts on methadone maintenance treatment." | 7.72 | Prevalence of HIV, hepatitis B, C and G virus infections among injecting drug users on methadone maintenance treatment in Maribor. ( Baklan, Z; Gorisek, JR; Pisec, A; Poljak, M, 2004) |
| "To investigate hepatitis C (HCV) and human immunodeficiency virus (HIV-1) prevalence in former opiate or heroin addicts currently in methadone maintenance treatment (MMT)." | 7.71 | Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment. ( Borg, L; Ho, A; Kreek, MJ; Lin, A; Melia, D; Piccolo, P, 2002) |
| "This study measured the extent and examined implications of hepatitis C (HCV) infection in a methadone maintenance treatment (MMT) population." | 7.71 | Hepatitis C in methadone maintenance patients: prevalence and public policy implications. ( Flynn, N; McCarthy, JJ, 2001) |
| "The high rates of hepatitis B exposure in injecting drug users on methadone treatment confirm the need for hepatitis B vaccination, particularly in view of their endemic hepatitis C infection." | 7.71 | Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. ( Carter, H; Hailwood, C; Hanlon, C; Massarotto, A; Robinson, G, 2001) |
| "This study evaluates the safety, tolerability, and efficacy of interferon/ribavirin combination therapy in methadone maintenance (MM) patients with active hepatitis C (HCV)." | 7.71 | Treating hepatitis C in methadone maintenance patients: an interim analysis. ( Sylvestre, DL, 2002) |
| " We studied the associations between retention in methadone treatment and drug use behaviors and incidence of hepatitis B and C in a cohort of IDUs in the Seattle, Washington, area." | 7.70 | Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. ( Hagan, H; Murrill, CS; Thiede, H, 2000) |
| "The objective of this study was to describe the incidence and prevalence of hepatitis C infection among clients of a methadone program in Queensland." | 7.69 | Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus. ( Denton, M; Plant, AJ; Selvey, LA, 1997) |
| " Multivariate linear regression to assess correlates of HCV knowledge post-intervention revealed that optimal dosage of MMT and having had an HIV test in the past year significantly increased HCV knowledge." | 6.84 | Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. ( Ali, SH; Altice, FL; Kamarulzaman, A; Mukherjee, TI; Pillai, V; Wickersham, JA, 2017) |
| "Individuals with opioid use disorders, including those on medication-assisted therapy such as methadone or buprenorphine, are a key demographic group that can benefit from HCV treatment given their high HCV prevalence; however, pharmacokinetic and pharmacodynamic drug interactions could blunt their utility." | 6.53 | Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. ( Bruce, RD; Friedland, G; Ogbuagu, O, 2016) |
| "all methadone users that were positive for anti-HCV antibodies were included in the study." | 5.56 | Linkage to care strategy for the micro-elimination of hepatitis C among parenteral drug users on methadone replacement therapy in Gipuzkoa. ( Almandoz Cortajarena, E; Arenas Ruiz-Tapiador, J; Arranz Díaz, S; Bujanda, L; Castiella Eguzkiza, A; Chouza Pérez, JM; Esandi González, FJ; Gil Fernández, B; Gómez García, A; Pérez Castaño, Y; Sánchez Iturri, MJ; Sanz Largo, V; Urtasun Lugea, I, 2020) |
| "Methadone treatment (exposure) was self-reported and severe FI (outcome) was measured using the Household Food Security Survey Module." | 5.48 | Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. ( Cooper, C; Cox, J; Hamelin, AM; Harper, S; Klein, MB; McLinden, T; Moodie, EEM; Rossi, C; Rourke, SB; Walmsley, SL, 2018) |
| "A methadone maintenance treatment (MMT) program to curb the dual epidemics of HIV/AIDS and drug use has been administered by China since 2004." | 5.46 | Spatial distribution of HIV, HCV, and co-infections among drug users in the southwestern border areas of China (2004-2014): a cohort study of a national methadone maintenance treatment program. ( He, C; Huang, W; Lan, G; Li, C; Li, M; Li, R; Liang, N; Peng, Z; Shen, Z; Tang, X; Zhong, F, 2017) |
| "Patients with opioid use disorders on opioid agonist therapy (OAT) have lower pain tolerance compared to controls." | 5.42 | Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders. ( Alford, DP; Cheng, DM; Edwards, RR; Liebschutz, JM; Lira, MC; Mao, J; Samet, JH; Tsui, JI; Winter, MR, 2015) |
| "Methadone maintenance treatment (MMT) is a major treatment regimen for opioid dependence." | 5.39 | Hepatitis C virus infection influences the S-methadone metabolite plasma concentration. ( Chang, YS; Ho, IK; Hsu, YT; Kuo, HW; Liu, SW; Liu, YL; Tsou, HH; Wang, SC; Wu, SL, 2013) |
| "Methadone maintenance treatment (MMT) has been available in Guangdong province, China since 2006." | 5.39 | High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province, China. ( Chen, W; Ling, L; Zhang, D; Zhang, L; Zou, X, 2013) |
| "Methadone maintenance treatment program patients were referred, evaluated by the internist and hepatologist in hepatitis clinic and provided HCV treatment with integration between both sites." | 5.38 | Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. ( Beeder, AB; Dimova, R; Kreek, MJ; Marks, KM; Martinez, AD; Talal, AH; Zeremski, M, 2012) |
| "For methadone, there was a non-significant 41 % increased advanced fibrosis risk in Whites and 51 % reduced risk in AA." | 5.38 | Finasteride and methadone use and risk of advanced hepatitis C related liver disease. ( El-Serag, HB; Hashmi, A; Kuzniarek, J; Ramsey, DJ; Tavakoli-Tabasi, S; White, DL, 2012) |
| "57% had a current non-substance use psychiatric disorder." | 5.35 | Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. ( Batki, SL; Canfield, KM; Ploutz-Snyder, R; Smyth, E, 2009) |
| "Methadone maintenance therapy for the treatment of opioid dependence continues to carry a social stigma." | 5.34 | Liver transplant and hepatitis C in methadone maintenance therapy: a case report. ( Bourgeois, JA; Craemer, E; Hancock, MM; Lester, L; Prosser, CC; Ransibrahmanakul, K; Rossaro, L, 2007) |
| "Methadone maintenance treatment reduces drug-related-harm." | 5.32 | [Prevalence of infection by HIV and hepatitis C virus in a cohort of patients on methadone treatment]. ( Aragonés, A; Barril, J; Esteban, J; Gimeno, C; Pellín, Mde L, 2003) |
| " However, there are no special HCV or HIV (human immunodeficiency virus)-related intervention programs that are tailored for drug users in China; to fill this gap, the purpose of this study was to explore HCV and HIV-related knowledge among drug users in MMT (methadone maintenance treatment) sites of China and to investigate the effectiveness of HCV and HIV-related education for improving the knowledge of IDUs (injection drug users) and their awareness of infection." | 5.30 | DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China. ( Du, J; Huang, LP; Li, Z; Li, ZB; Wang, J; Zhan, GL; Zhang, JY; Zhang, L; Zhao, M, 2019) |
| "Hepatitis C virus (HCV) is a prevalent chronic blood-borne infection among opioid-dependent patients on methadone maintenance treatment (MMT)." | 5.16 | Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication. ( Acosta, A; Altice, FL; Bruce, RD; Eiserman, J; Gote, C; Lim, JK, 2012) |
| "To examine hepatic enzyme test results throughout the course of pregnancy in women maintained on methadone or buprenorphine." | 5.16 | Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication. ( Coyle, MG; Heil, SH; Holbrook, AM; Jones, HE; Kaltenbach, K; Martin, PR; McNicholas, LF; O'Grady, KE; Stine, SM, 2012) |
| "Most methadone-maintained injection drug users (IDUs) have been infected with hepatitis C virus (HCV), but few initiate HCV treatment." | 5.15 | Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics. ( Arnsten, JH; Berg, KM; Hidalgo, J; Li, X; Litwin, AH, 2011) |
| " There was screening for patients attending general practice for methadone maintenance treatment for hepatitis C and referral of anti-HCV antibody positive patients to a specialist hepatology department for assessment." | 5.12 | Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation. ( Bury, G; Cullen, W; Kelly, Y; Langton, D; Staines, A; Stanley, J, 2006) |
| "To examine the long-term impact of methadone maintenance treatment (MMT) on mortality, re-incarceration and hepatitis C seroconversion in imprisoned male heroin users." | 5.11 | Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. ( Dolan, KA; Kaldor, J; Shearer, J; White, B; Wodak, AD; Zhou, J, 2005) |
| "A prospective study was conducted on the evolution of serum transaminases in 116 patients infected with hepatitis C virus (HCV), parenteral drug abusers, included for 6 months in treatment programs with methadone, naltrexone or "drug free" regimen." | 5.08 | [Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection]. ( Gutiérrez Mora, E; Lozano Polo, JL; Martínez Pérez, V; Santamaría Gutiérrez, J; Vada Sánchez, J; Vallejo Correas, JA, 1997) |
| " After adjusting for on or off MMT, age, sex, marital status, education level, maximum methadone dose, and comorbidities (human immunodeficiency virus, depression, hepatitis C virus, hepatitis B virus, alcoholic liver disease, and cardiovascular disease), the long group had a lower risk of death (hazard ratio = 0." | 4.31 | Reduced mortality in patients with extended duration of methadone maintenance treatment: a five-year retrospective nationwide study. ( Ho, IK; Huang, CL; Lee, CW; Lin, CL; Lin, WC; Tsai, IJ; Wang, RY, 2023) |
| "Although hepatitis C virus (HCV) prevails in patients receiving methadone maintenance treatment (MMT), most do not receive anti-HCV therapy." | 4.12 | Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic. ( Chan, HW; Chang, TT; Changchien, TC; Chen, CC; Chen, TH; Huang, CK; Lin, PC; Sie, YT; Tai, CM; Tsai, CT; Tseng, CH; Wang, DW; Yen, YC; Yu, ML, 2022) |
| "To determine the prevalence of continued illicit drug use among people enrolled in methadone maintenance treatment (MMT), the association between hepatitis C status and methadone dosage, and the predictors for illicit drug abstinence during MMT." | 4.12 | Methadone Maintenance Treatment for Opioid Dependents: a Retrospective Study. ( Abdul Rashid, Q; Jamaluddin, R; Khalid, K; Mohammad Yusoff, MZA; Ooi, YT, 2022) |
| "There is a dearth of research on hepatitis C virus (HCV) treatment uptake among people who inject drugs (PWIDs) and receive methadone substitution treatment (MST) in Eastern Europe and Central Asia countries." | 4.02 | Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia. ( Gamkrelidze, A; Getia, V; Gvinjilia, L; Khonelidze, I; Kuchuloria, T; Stvilia, K; Tsereteli, M; Vephkvadze, N, 2021) |
| "Despite the efforts to curb viral hepatitis and HIV infections through Methadone clinics, infection rates among people who use drugs are still high and the general knowledge on preventive measures is inadequate." | 4.02 | Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study. ( Bakshi, FA; Gunda, DW; Jaka, H; Kalokola, F; Kilonzo, SB; Majinge, DC; Manyiri, PM; Mtui, G; Shao, ER; Stephano, A, 2021) |
| "The aim of this study was to determine the influence of ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms on methadone metabolism in patients with hepatitis C virus (HCV) undergoing methadone maintenance treatment (MMT)." | 3.96 | ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients. ( Ključević, Ž; Kuret, S; Sutlović, D, 2020) |
| "People on methadone treatment have increased their life expectancy, aging prematurely with comorbidities." | 3.91 | [Aging in a methadone maintenance program. A perspective from the framework of social determinants of health]. ( Gutiérrez-Cáceres, S; Pedraz-Marcos, A; Serrano-Gallardo, P, 2019) |
| "While most methadone maintenance treatment (MMT) patients have hepatitis C (HCV), less than 11% initiate treatment." | 3.91 | Perceptions of Barriers and Benefits of HCV Treatment and Correlates to Treatment Intention in Methadone Patients. ( Bass, SB; Gashat, MT; Gutierrez, M; Jessop, AB, 2019) |
| "We aimed to evaluate the status and barriers related to hepatitis C virus (HCV) treatment among Chinese methadone maintenance treatment (MMT) clients, and the willingness and barriers of patients to accept directly observed treatment (DOT) service and oral direct-acting antivirals (DAAs)." | 3.91 | Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study. ( Chen, W; Gong, C; Ling, L; Liu, Y; Zou, X, 2019) |
| "Despite high hepatitis C virus (HCV) prevalence, opioid use disorder (OUD) patients on methadone rarely engage in HCV treatment." | 3.91 | Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone. ( Andrews, P; Brown, LS; Chen, Y; Markatou, M; Mcleod, A; Sylvester, C; Talal, AH, 2019) |
| "The majority of patients undergoing methadone maintenance treatment (MMT) are neither examined nor treated for hepatitis C virus (HCV) infection." | 3.91 | Integrated care for methadone maintenance patients with hepatitis C virus infection. ( Bair, MJ; Chang, TT; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Tai, CM; Tseng, CH; Yeh, ML; Yen, YC; Yu, ML, 2019) |
| "An estimated 70-90% of current methadone users have Hepatitis C (HCV)." | 3.88 | Mapping the Barriers and Facilitators of HCV Treatment Initiation in Methadone Maintenance Therapy Patients: Implications for Intervention Development. ( Al Hajji, M; Bass, SB; Gashat, M; Gutierrez, M; Jessop, A; Maurer, L, 2018) |
| "Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections among methadone maintenance treatment (MMT) participants remain high." | 3.88 | Strategies to control HIV and HCV in methadone maintenance treatment in Guangdong Province, China: a system dynamic modeling study. ( Chen, W; Gong, C; Ling, L; Liu, Y; Xia, Y; Xu, Y; Zou, X, 2018) |
| "This paper describes the development of a mobile health tool to facilitate Hepatitis C (HCV) treatment decision making in methadone patients." | 3.88 | Take Charge, Get Cured: The development and user testing of a culturally targeted mHealth decision tool on HCV treatment initiation for methadone patients. ( Alhajji, M; Bauerle Bass, S; Forry, J; Gashat, M; Jessop, A; Maurer, L, 2018) |
| "To assess trends and related factors in HIV and/or hepatitis C virus (HCV) antibody testing and infection among injection drug users (IDUs) newly entering methadone maintenance treatment (MMT) in Guangdong Province, China." | 3.85 | Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study. ( Chen, W; Ling, L; Liu, Y; Zou, X, 2017) |
| "The aim of this study was to characterize the epidemiology and disease related to hepatitis C in a population attending a low-threshold methadone program." | 3.85 | Hepatitis C in a Mobile Low-Threshold Methadone Program. ( Água-Doce, I; Balsa, C; Belo, E; Coutinho, R; Lopes, P; Loureiro, R; Martins, HC; Pádua, E; Pereira, C; Silva, MJ, 2017) |
| "Methadone maintenance treatment patients in Wuhan, China show a high prevalence of hepatitis C virus at admission (72." | 3.81 | Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. ( Chawarski, MC; Desrosiers, A; Liu, M; Liu, P; Luo, L; Peng, J; Schottenfeld, R; Wang, X; Xie, N; Zhou, S; Zhou, W, 2015) |
| "Routinely collected data included: demographic information; drug use, sexual and criminal behaviours; status of infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV) and syphilis; random urine-opiate test results; and the daily methadone dose received." | 3.81 | Who uses methadone services in China? Monitoring the world's largest methadone programme. ( Cao, X; Liu, E; Luo, W; Mi, G; Pang, L; Rou, K; Sullivan, SG; Wang, C; Wu, Z; Yin, W, 2015) |
| "This study explores the trends and associated factors of HIV, hepatitis C virus (HCV) and syphilis seroconversion among Chinese methadone maintenance treatment (MMT) clients over a follow-up period of up to 7 years." | 3.81 | Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort study. ( Ling, L; Zhang, L; Zou, X, 2015) |
| "Prior research has demonstrated neuropsychological (NP) impairment in persons with histories of injection drug use (IDU), hepatitis C virus (HCV) infection, and methadone maintenance treatment (MMT), individually, but little is known about the NP effects of these three risk factors in combination." | 3.80 | Absence of neurocognitive impairment in a large Chinese sample of HCV-infected injection drug users receiving methadone treatment. ( Duarte, N; Franklin, DR; Grant, I; Gupta, S; Hampton Atkinson, J; Heaton, RK; Iudicello, JE; Jin, H; Knight, A; Letendre, S; Li, J; Riggs, PK; Shi, C; Wu, Z; Yu, X, 2014) |
| "The objective of this study was to assess craving and mood related to opioid and cocaine use among asymptomatic hepatitis C virus (HCV)+ and HCV- methadone patients who have not started antiviral treatment." | 3.80 | Substance use and hepatitis C: an ecological momentary assessment study. ( Epstein, DH; Lin, JL; Mezghanni, M; Phillips, KA; Preston, KL; Vahabzadeh, M, 2014) |
| "To determine the relationship between methadone maintenance therapy (MMT) and hepatitis C (HCV) seroconversion among illicit drug users." | 3.80 | The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. ( Dias Lima, V; Fairbairn, N; Grebely, J; Kerr, T; Montaner, J; Nolan, S; Wood, E, 2014) |
| "This study investigates the prevalence and correlates of hepatitis C virus (HCV) infections among heroin dependent individuals who received methadone maintenance therapy in Taiwan." | 3.79 | High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan. ( Chang, TJ; Chen, VC; Chou, JY; Gossop, M; Lee, PC; Lin, TY; Ng, MH; Shao, WC, 2013) |
| "Depression and hepatitis C virus (HCV) infection are two common conditions among heroin users in methadone maintenance treatment (MMT)." | 3.79 | Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China. ( Du, J; Mandel, JS; Page, K; Wang, Z; Xiao, Z; Zhao, M, 2013) |
| "We used a 25-item, self-administered questionnaire to assess staff's perceived barriers and willingness to engage in onsite treatment of hepatitis C virus (HCV) at the Beth Israel Medical Center methadone maintenance treatment program (MMTP) at its Harlem sites." | 3.79 | Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment. ( Des Jarlais, DC; Dimova, RB; Perlman, DC; Peterson, RH; Seewald, R; Talal, AH; Zeremski, M, 2013) |
| "This study aims to: (1) document the prevalence of hepatitis C virus (HCV) among methadone maintenance treatment (MMT) patients in Kunming and Shanghai; (2) examine risk factors for HCV by comparing those who tested positive with those who were negative and (3) examine if HCV serostatus is related to attitudes toward MMT." | 3.78 | Hepatitis C among methadone maintenance treatment patients in Shanghai and Kunming, China. ( Chang, YJ; Du, J; Evans, E; Hser, Y; Li, J; Peng, CY; Zhao, M, 2012) |
| "The aim was to investigate hepatitis C virus (HCV) knowledge and alcohol consumption among patients (n = 114) in a methadone maintenance treatment (MMT) clinic in Shanghai." | 3.78 | Hepatitis C knowledge and alcohol consumption among patients receiving methadone maintenance treatment in Shanghai, China. ( Du, J; Wang, Z; Xie, B; Zhao, M, 2012) |
| "To provide evidence for policy makers for human immunodeficiency virus (HIV) prevention and control, we investigated HIV, syphilis, and hepatitis C virus (HCV) infection and the availability of methadone maintenance treatment (MMT) among migrant drug users in Beijing." | 3.78 | High prevalence of HIV, syphilis and HCV, and low methadone maintenance treatment in a migrant population in Beijing. ( Cao, X; Chu, P; Jia, Z; Li, D; Li, S; Liu, Z; Lu, L; Ruan, Y; Yang, Y, 2012) |
| " Data on HIV and hepatitis C virus (HCV) infections, methadone dosage, and morphine in the urine were retrieved from patient files on the clinical premises, with permission of the participants." | 3.77 | Clinical characteristics and risk behavior as a function of HIV status among heroin users enrolled in methadone treatment in northern Taiwan. ( Chou, YC; Chuang, P; Huang, CW; Lee, TS; Liu, YL; Shen, HC; Shih, CY; Wang, BE; Wu, WH; Yen, MY, 2011) |
| "To study the risk factors for seroconversion to hepatitis C virus (HCV) infection since admission to methadone maintenance treatment (MMT) and to characterize the seronegative admitted group." | 3.77 | Low risk for hepatitis C seroconversion in methadone maintenance treatment. ( Adelson, M; Peles, E; Rados, V; Schreiber, S, 2011) |
| " Additional factors associated with BMD decline were: postmenopausal status, lower BMI, and methadone use at the lumbar spine; postmenopausal status and hepatitis C seropositivity at the femoral neck; and postmenopausal status, age, smoking, and lower BMI at the total hip (all p<." | 3.77 | Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: Association between methadone use and bone loss. ( Cohen, HW; Freeman, R; Santoro, N; Schoenbaum, EE; Sharma, A, 2011) |
| "Hepatitis C virus (HCV) knowledge, attitudes, beliefs, and experiences (KABE) of 64 HCV antibody positive methadone maintenance treatment (MMT) patients were assessed in conjunction with acceptability of an on-site semi-structured HCV education session, HCV RNA diagnostic testing, HCV treatment motivational assessment, and initiation of HCV treatment." | 3.76 | Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection. ( Batki, SL; Canfield, KM; Smyth, E, 2010) |
| " We report the case of a 50-year-old man with hepatitis C cirrhosis who demonstrated dramatic improvement in HPS after withdrawal from chronic methadone therapy." | 3.76 | Improvement in hepatopulmonary syndrome after methadone withdrawal: a case report with implications for disease mechanism. ( Lau, EM; McCaughan, G; Torzillo, PJ, 2010) |
| "To describe the patterns of screening for hepatitis C virus (HCV) infection in methadone-maintained pregnant women and their infants." | 3.75 | Screening for hepatitis C virus infection in methadone-maintained mothers and their infants. ( An, EI; Leroi, MJ; Liu, AJ; Murray, HG; Nanan, RK; Tetstall, E, 2009) |
| "The purpose of this article was to investigate the personal and social barriers experienced by methadone maintained clients when seeking treatment for alcohol abuse along with strategies for engaging such clients in treatment programs." | 3.74 | Alcohol use reduction program in methadone maintained individuals with hepatitis C virus infection. ( Cohen, A; de Castro, V; Khalilifard, F; Marfisee, M; McNeese-Smith, D; Nyamathi, A; Nyamathi, K; Shoptaw, S, 2008) |
| "We examined the impact of methadone maintenance treatment (MMT) on risk behaviors for transmission of blood-borne diseases in polydrug users who had tested positive or negative for hepatitis C virus (HCV)." | 3.74 | Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance. ( Belendiuk, KA; Epstein, DH; Preston, KL; Schmittner, J; Willner-Reid, J, 2008) |
| "Prevalence of buprenorphine injection, associations with location, buprenorphine as prescribed pharmacotherapy, markers of hepatitis C virus (HCV) exposure and risk behaviours for HCV." | 3.74 | Buprenorphine injection in Melbourne, Australia--an update. ( Aitken, CK; Hellard, ME; Higgs, PG, 2008) |
| "Despite the high prevalence of hepatitis C virus (HCV) infection among drug users enrolled in methadone maintenance treatment programs, few drug users are being treated with combination therapy." | 3.73 | Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. ( Gourevitch, MN; Litwin, AH; Soloway, I, 2005) |
| "The majority of injecting drug users in Ireland are infected with hepatitis C (HCV) and many attend general practice for methadone maintenance treatment." | 3.73 | Experience of hepatitis C among current or former heroin users attending general practice. ( Bury, G; Cullen, W; Kelly, Y; Langton, D; Stanley, J, 2005) |
| "The safety, efficacy, and tolerability of nelfinavir (NFV)-containing antiretroviral therapy were evaluated in patients coinfected with HIV and hepatitis C undergoing methadone maintenance at an urban outpatient opioid treatment program serving a minority adult population." | 3.73 | Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance. ( Brown, LS; Chu, M; Kritz, S; Madray, C, 2006) |
| " Severity of psychological distress was related to current substance-related diagnoses, benzodiazepine abuse, higher methadone dosage, risk-taking behavior and the presence of hepatitis C." | 3.73 | Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. ( Adelson, M; Bleich, A; Gelkopf, M; Melamed, Y; Weizman, T, 2006) |
| "The survey of viral infections in the liver investigated by means of serological markers of hepatitis A, B and C in drug addicts on methadone maintenance treatment is important for the next procedures." | 3.72 | [Prevalence of serological markers of viral hepatitis B and hepatitis C in drug-dependent individuals treated at the Drop Methadone Center in Prague]. ( Urbánek, P; Wilczek, H, 2003) |
| " Hepatitis C virus (HCV) is highly prevalent among intravenous drug users (IDUs) and the 'offer' of a serological test for HCV antibodies is now seen as a national standard within drug misuse services, including GP methadone clinics." | 3.72 | Finding a vein or obtaining consent: a qualitative study of hepatitis C testing in GP methadone clinics. ( Chew-Graham, C; Perry, M, 2003) |
| "Approximately 85% of patients receiving methadone maintenance therapy (MMT) for opiate dependence in the United States are infected with hepatitis C virus (HCV)." | 3.72 | A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients. ( Atanda, A; Barnett, R; DePiano, M; Lynch, KG; Olthoff, KM; Weinrieb, RM, 2004) |
| "The cost-effectiveness of hepatitis C virus (HCV) anti-viral therapy for injecting drug users (IDUs) on methadone maintenance is important because the majority have chronic infections that remain untreated." | 3.72 | What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? ( Green, FT; Sellman, JD; Sheerin, IG, 2004) |
| "The prevalence of human immunodeficiency virus (HIV) infection and hepatitis B, C, and G virus infections was determined in a selected group of 40 intravenous drug addicts on methadone maintenance treatment." | 3.72 | Prevalence of HIV, hepatitis B, C and G virus infections among injecting drug users on methadone maintenance treatment in Maribor. ( Baklan, Z; Gorisek, JR; Pisec, A; Poljak, M, 2004) |
| "To investigate hepatitis C (HCV) and human immunodeficiency virus (HIV-1) prevalence in former opiate or heroin addicts currently in methadone maintenance treatment (MMT)." | 3.71 | Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment. ( Borg, L; Ho, A; Kreek, MJ; Lin, A; Melia, D; Piccolo, P, 2002) |
| "This study measured the extent and examined implications of hepatitis C (HCV) infection in a methadone maintenance treatment (MMT) population." | 3.71 | Hepatitis C in methadone maintenance patients: prevalence and public policy implications. ( Flynn, N; McCarthy, JJ, 2001) |
| "The high rates of hepatitis B exposure in injecting drug users on methadone treatment confirm the need for hepatitis B vaccination, particularly in view of their endemic hepatitis C infection." | 3.71 | Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination. ( Carter, H; Hailwood, C; Hanlon, C; Massarotto, A; Robinson, G, 2001) |
| " The descriptive analysis in heroin-assisted treatment showed a reduction in infection risk for viral hepatitis corresponding to the lower risk behaviour of patients." | 3.71 | HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme. ( Blättler, R; Gutzwiller, F; Steffen, T; Zwahlen, M, 2001) |
| "This study evaluates the safety, tolerability, and efficacy of interferon/ribavirin combination therapy in methadone maintenance (MM) patients with active hepatitis C (HCV)." | 3.71 | Treating hepatitis C in methadone maintenance patients: an interim analysis. ( Sylvestre, DL, 2002) |
| " We studied the associations between retention in methadone treatment and drug use behaviors and incidence of hepatitis B and C in a cohort of IDUs in the Seattle, Washington, area." | 3.70 | Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area. ( Hagan, H; Murrill, CS; Thiede, H, 2000) |
| "The objective of this study was to describe the incidence and prevalence of hepatitis C infection among clients of a methadone program in Queensland." | 3.69 | Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus. ( Denton, M; Plant, AJ; Selvey, LA, 1997) |
| " Multivariate linear regression to assess correlates of HCV knowledge post-intervention revealed that optimal dosage of MMT and having had an HIV test in the past year significantly increased HCV knowledge." | 2.84 | Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia. ( Ali, SH; Altice, FL; Kamarulzaman, A; Mukherjee, TI; Pillai, V; Wickersham, JA, 2017) |
| " The average DAM dosage was 274." | 2.72 | Controlled trial of prescribed heroin in the treatment of opioid addiction. ( Carrasco, F; March, JC; Oviedo-Joekes, E; Perea-Milla, E, 2006) |
| "Methadone exposure was either decreased or unchanged when it was coadministered with weak to strong CYP3A inhibitors or a moderate CYP3A4 inducer." | 2.61 | Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned. ( Lakota, EA; Patel, V; Sahajwalla, CG; Volpe, DA; Xu, Y; Younis, IR, 2019) |
| "Individuals with opioid use disorders, including those on medication-assisted therapy such as methadone or buprenorphine, are a key demographic group that can benefit from HCV treatment given their high HCV prevalence; however, pharmacokinetic and pharmacodynamic drug interactions could blunt their utility." | 2.53 | Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. ( Bruce, RD; Friedland, G; Ogbuagu, O, 2016) |
| "To describe potential drug-drug interactions in the area of HIV/hepatitis C virus (HCV) coinfection and injection drug use, including those between antiretrovirals (ARVs), direct-acting antivirals (DAAs), and opioid-agonist therapy, and to supply a practical approach to their management." | 2.52 | Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy. ( Christensen, S; Gillessen, A; Hanhoff, N; Meemken, L; Tseng, A, 2015) |
| "Methadone maintenance treatment (MMT) was implemented in China since 2004." | 2.48 | HIV and HCV prevalence among entrants to methadone maintenance treatment clinics in China: a systematic review and meta-analysis. ( Chow, EP; Liang, Y; Wang, Y; Wilson, DP; Zhang, L; Zhuang, X, 2012) |
| "Methadone maintenance treatment (MMT) has rapidly expanded in China, from 8 pilot sites to 696 clinics covering 27 provinces, during 2004-2010." | 2.48 | Risk factors associated with HIV/HCV infection among entrants in methadone maintenance treatment clinics in China: a systematic review and meta-analysis. ( Chow, EP; Liang, Y; Wang, Y; Wilson, DP; Zhang, L; Zhuang, X, 2012) |
| "The methadone maintenance treatment (MMT) program has run for more than 20 years and the public has become more tolerant of addicts." | 2.44 | Comparison of drug abuse in Germany and China. ( Fang, YX; Lu, L; Michels, II; Zhao, D; Zhao, LY, 2007) |
| "Methadone has significant, adverse drug-drug interactions with many antiretroviral therapeutic agents that can contribute to nonadherence and poor clinical outcomes in this high-risk population." | 2.43 | Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. ( McCance-Katz, EF, 2005) |
| "We estimated the cascade of care for opioid use disorder and identified factors associated with care engagement for people with opioid use disorder (PWOUD) provincially." | 1.56 | The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada. ( Homayra, F; Hongdilokkul, N; McGowan, G; Min, JE; Nosyk, B; Pearce, LA; Piske, M; Socias, ME; Zhou, H, 2020) |
| "all methadone users that were positive for anti-HCV antibodies were included in the study." | 1.56 | Linkage to care strategy for the micro-elimination of hepatitis C among parenteral drug users on methadone replacement therapy in Gipuzkoa. ( Almandoz Cortajarena, E; Arenas Ruiz-Tapiador, J; Arranz Díaz, S; Bujanda, L; Castiella Eguzkiza, A; Chouza Pérez, JM; Esandi González, FJ; Gil Fernández, B; Gómez García, A; Pérez Castaño, Y; Sánchez Iturri, MJ; Sanz Largo, V; Urtasun Lugea, I, 2020) |
| "Opioid agonist treatment is considered important in preventing acquisition of hepatitis C virus (HCV) among people who inject drugs; however, the role of dosage in opioid agonist treatment is unclear." | 1.51 | Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs. ( Artenie, AA; Bruneau, J; Gauvin, L; Høj, S; Jacka, B; Jutras-Aswad, D; Minoyan, N; Roy, É; Zang, G, 2019) |
| "Methadone treatment (exposure) was self-reported and severe FI (outcome) was measured using the Household Food Security Survey Module." | 1.48 | Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis. ( Cooper, C; Cox, J; Hamelin, AM; Harper, S; Klein, MB; McLinden, T; Moodie, EEM; Rossi, C; Rourke, SB; Walmsley, SL, 2018) |
| "Methadone status was not associated to HCV seroconversion." | 1.48 | HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination. ( Alvaro-Meca, A; Cuevas, G; Gutiérrez, J; Moreno, S; Ryan, P; Troya, J; Valencia La Rosa, J, 2018) |
| "A methadone maintenance treatment (MMT) program to curb the dual epidemics of HIV/AIDS and drug use has been administered by China since 2004." | 1.46 | Spatial distribution of HIV, HCV, and co-infections among drug users in the southwestern border areas of China (2004-2014): a cohort study of a national methadone maintenance treatment program. ( He, C; Huang, W; Lan, G; Li, C; Li, M; Li, R; Liang, N; Peng, Z; Shen, Z; Tang, X; Zhong, F, 2017) |
| "Patients with opioid use disorders on opioid agonist therapy (OAT) have lower pain tolerance compared to controls." | 1.42 | Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders. ( Alford, DP; Cheng, DM; Edwards, RR; Liebschutz, JM; Lira, MC; Mao, J; Samet, JH; Tsui, JI; Winter, MR, 2015) |
| "The objective was to study substance abuse, infectious disease, and patient outcomes (retention and substance abuse abstinence) over 2 decades in a large methadone maintenance treatment (MMT) facility within a tertiary-referral medical center." | 1.40 | Trends in substance abuse and infectious disease over 20 years in a large methadone maintenance treatment (MMT) clinic in Israel. ( Adelson, M; Peles, E; Schreiber, S, 2014) |
| "Methadone maintenance treatment (MMT) is a major treatment regimen for opioid dependence." | 1.39 | Hepatitis C virus infection influences the S-methadone metabolite plasma concentration. ( Chang, YS; Ho, IK; Hsu, YT; Kuo, HW; Liu, SW; Liu, YL; Tsou, HH; Wang, SC; Wu, SL, 2013) |
| "Methadone maintenance treatment (MMT) has been available in Guangdong province, China since 2006." | 1.39 | High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province, China. ( Chen, W; Ling, L; Zhang, D; Zhang, L; Zou, X, 2013) |
| "Methadone maintenance treatment is evidenced as a successful harm reduction initiative in regard to the prevention of blood borne viruses and other injecting related harms." | 1.39 | Methadone diversion as a protective strategy: the harm reduction potential of 'generous constraints'. ( Harris, M; Rhodes, T, 2013) |
| "Methadone maintenance treatment program patients were referred, evaluated by the internist and hepatologist in hepatitis clinic and provided HCV treatment with integration between both sites." | 1.38 | Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance. ( Beeder, AB; Dimova, R; Kreek, MJ; Marks, KM; Martinez, AD; Talal, AH; Zeremski, M, 2012) |
| " Clinically significant MDIs included withdrawal symptoms, which were found among MMTP patients co-administered with buprenorphine or tramadol; severe QTc prolongation effect, which might be associated with use of haloperidol or droperidol; and additive CNS and respiratory depression, which could result from use of methadone in combination with chlorpromazine or thioridazine." | 1.38 | Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan. ( Lee, HY; Li, JH; Tang, HP; Wu, JS; Wu, LT; Yen, CF, 2012) |
| "For methadone, there was a non-significant 41 % increased advanced fibrosis risk in Whites and 51 % reduced risk in AA." | 1.38 | Finasteride and methadone use and risk of advanced hepatitis C related liver disease. ( El-Serag, HB; Hashmi, A; Kuzniarek, J; Ramsey, DJ; Tavakoli-Tabasi, S; White, DL, 2012) |
| "Uptake of treatment for hepatitis C virus (HCV) infection is very low particularly among people who have injected drugs." | 1.36 | Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals. ( Hopwood, M; Newland, J; Rance, J; Treloar, C, 2010) |
| "57% had a current non-substance use psychiatric disorder." | 1.35 | Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection. ( Batki, SL; Canfield, KM; Ploutz-Snyder, R; Smyth, E, 2009) |
| "The association between substance use, rates of completion of therapy and rates of response were assessed using multivariable regression analyses." | 1.35 | Treatment of hepatitis C infection for current or former substance abusers in a community setting. ( Daiter, J; John-Baptiste, A; Krahn, M; Lingley, M; Nedd-Roderique, T; Teplin, D; Tomlinson, G; Varenbut, M, 2009) |
| "Methadone maintenance therapy for the treatment of opioid dependence continues to carry a social stigma." | 1.34 | Liver transplant and hepatitis C in methadone maintenance therapy: a case report. ( Bourgeois, JA; Craemer, E; Hancock, MM; Lester, L; Prosser, CC; Ransibrahmanakul, K; Rossaro, L, 2007) |
| " The second part was a cross-sectional study (n = 223 doctors), which consisted of a target-week assessment of 2,694 consecutive patients to determine (a) the severity and problem profiles and treatment targets; (b) the choice and dosage scheme of the substitution drug; (c) past and current interventions, including treatment of comorbid hepatitis C; and (d) cross-sectional differences between the two drugs with regard to comorbidity, clinical course, acceptance/compliance and social integration." | 1.33 | Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study. ( Apelt, SM; Backmund, M; Bühringer, G; Gastpar, M; Gölz, J; Klotsche, J; Kraus, MR; Pittrow, D; Siegert, J; Soyka, M; Tretter, F; Wittchen, HU, 2005) |
| "Methadone maintenance treatment of opiate addiction is highly effective at reducing drug use, drug-related criminal activity, and risk of HIV transmission." | 1.33 | Linkage with methadone treatment upon release from incarceration: a promising opportunity. ( Clarke, J; Key, RG; McKenzie, M; Poshkus, M; Rich, JD; Shield, DC; Wolf, FA, 2005) |
| "Methadone is a synthetic opiate used in the treatment of opiate addiction." | 1.33 | Dental management of patients taking methadone. ( Graham, CH; Meechan, JG, 2005) |
| "Methadone maintenance treatment reduces drug-related-harm." | 1.32 | [Prevalence of infection by HIV and hepatitis C virus in a cohort of patients on methadone treatment]. ( Aragonés, A; Barril, J; Esteban, J; Gimeno, C; Pellín, Mde L, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (4.76) | 18.2507 |
| 2000's | 84 (36.36) | 29.6817 |
| 2010's | 118 (51.08) | 24.3611 |
| 2020's | 18 (7.79) | 2.80 |
| Authors | Studies |
|---|---|
| Jiménez-Treviño, L | 2 |
| Martínez-Cao, C | 1 |
| Sánchez-Lasheras, F | 2 |
| Iglesias, C | 1 |
| Antuña, MJ | 1 |
| Riera, L | 1 |
| Sáiz-Martínez, PA | 1 |
| Bobes, J | 2 |
| Tai, CM | 2 |
| Huang, CK | 1 |
| Changchien, TC | 1 |
| Lin, PC | 1 |
| Wang, DW | 1 |
| Chang, TT | 2 |
| Chan, HW | 1 |
| Chen, TH | 1 |
| Tseng, CH | 2 |
| Chen, CC | 1 |
| Tsai, CT | 1 |
| Sie, YT | 1 |
| Yen, YC | 2 |
| Yu, ML | 2 |
| Lier, AJ | 1 |
| Seval, N | 1 |
| Vander Wyk, B | 1 |
| Di Paola, A | 1 |
| Springer, SA | 1 |
| Khalid, K | 1 |
| Ooi, YT | 1 |
| Abdul Rashid, Q | 1 |
| Mohammad Yusoff, MZA | 1 |
| Jamaluddin, R | 1 |
| Yee, WL | 1 |
| Draper, B | 1 |
| Myint, KT | 1 |
| Min, W | 1 |
| Htay, H | 1 |
| O'Keefe, D | 1 |
| Hellard, M | 2 |
| Su, WW | 1 |
| Yang, CC | 2 |
| Chang, RW | 1 |
| Yeh, YH | 1 |
| Yen, HH | 1 |
| Lee, YL | 1 |
| Liu, CE | 1 |
| Liang, SY | 1 |
| Sung, ML | 1 |
| Ko, SY | 1 |
| Kuo, CY | 1 |
| Chen, SL | 1 |
| Yeh, YP | 1 |
| Hu, TH | 1 |
| Akiyama, MJ | 1 |
| Columbus, D | 1 |
| MacDonald, R | 1 |
| Jordan, AO | 1 |
| Schwartz, J | 1 |
| Litwin, AH | 5 |
| Eckhardt, B | 1 |
| Carmody, E | 1 |
| Gutiérrez-Cáceres, S | 1 |
| Pedraz-Marcos, A | 1 |
| Serrano-Gallardo, P | 1 |
| Zhang, JY | 1 |
| Li, ZB | 2 |
| Zhang, L | 7 |
| Wang, J | 2 |
| Huang, LP | 2 |
| Zhan, GL | 1 |
| Li, Z | 1 |
| Du, J | 6 |
| Zhao, M | 7 |
| Alam, F | 1 |
| Wright, N | 1 |
| Roberts, P | 1 |
| Dhadley, S | 1 |
| Townley, J | 1 |
| Webster, R | 1 |
| Jessop, AB | 2 |
| Bass, SB | 3 |
| Gutierrez, M | 2 |
| Gashat, MT | 2 |
| Liu, Y | 4 |
| Zou, X | 5 |
| Chen, W | 6 |
| Gong, C | 2 |
| Ling, L | 7 |
| Brajuha, J | 1 |
| Alhajji, M | 2 |
| Burke, M | 1 |
| Wellington, C | 1 |
| Ventriglia, N | 1 |
| Coleman, J | 1 |
| D'Avanzo, P | 1 |
| Piske, M | 1 |
| Zhou, H | 1 |
| Min, JE | 1 |
| Hongdilokkul, N | 1 |
| Pearce, LA | 1 |
| Homayra, F | 1 |
| Socias, ME | 2 |
| McGowan, G | 1 |
| Nosyk, B | 1 |
| Ordak, M | 1 |
| Nasierowski, T | 1 |
| Pawlik, K | 1 |
| Muszynska, E | 1 |
| Bujalska-Zadrozny, M | 1 |
| Pérez Castaño, Y | 1 |
| Chouza Pérez, JM | 1 |
| Sanz Largo, V | 1 |
| Almandoz Cortajarena, E | 1 |
| Gómez García, A | 1 |
| Esandi González, FJ | 1 |
| Castiella Eguzkiza, A | 1 |
| Arranz Díaz, S | 1 |
| Urtasun Lugea, I | 1 |
| Sánchez Iturri, MJ | 1 |
| Gil Fernández, B | 1 |
| Bujanda, L | 1 |
| Arenas Ruiz-Tapiador, J | 1 |
| Byrne, C | 1 |
| Radley, A | 1 |
| Inglis, SK | 1 |
| Beer, LJZ | 1 |
| Palmer, N | 1 |
| Pham, MD | 1 |
| Healy, B | 1 |
| Doyle, JS | 1 |
| Donnan, P | 1 |
| Dillon, JF | 1 |
| Jordan, AE | 4 |
| Cleland, CM | 2 |
| Schackman, BR | 2 |
| Wyka, K | 2 |
| Perlman, DC | 5 |
| Nash, D | 2 |
| Sutlović, D | 1 |
| Ključević, Ž | 1 |
| Kuret, S | 1 |
| Krekulová, L | 1 |
| Vavrinčíková, L | 1 |
| Huang, CL | 1 |
| Tsai, IJ | 1 |
| Lin, WC | 1 |
| Lin, CL | 1 |
| Ho, IK | 3 |
| Wang, RY | 1 |
| Lee, CW | 1 |
| Stvilia, K | 1 |
| Vephkvadze, N | 1 |
| Gamkrelidze, A | 1 |
| Khonelidze, I | 1 |
| Getia, V | 1 |
| Tsereteli, M | 1 |
| Gvinjilia, L | 1 |
| Kuchuloria, T | 1 |
| Kilonzo, SB | 1 |
| Gunda, DW | 1 |
| Majinge, DC | 1 |
| Jaka, H | 1 |
| Manyiri, PM | 1 |
| Kalokola, F | 1 |
| Mtui, G | 1 |
| Shao, ER | 1 |
| Bakshi, FA | 1 |
| Stephano, A | 1 |
| Roncero, C | 1 |
| Fuster, D | 1 |
| Palma-Álvarez, RF | 1 |
| Rodriguez-Cintas, L | 1 |
| Martinez-Luna, N | 1 |
| Álvarez, FJ | 1 |
| Kenworthy, J | 1 |
| Yi, Y | 1 |
| Wright, A | 1 |
| Brown, J | 1 |
| Maria Madrigal, A | 1 |
| Dunlop, WCN | 1 |
| Birger, RB | 1 |
| Le, T | 1 |
| Kouyos, RD | 1 |
| Grenfell, BT | 1 |
| Hallett, TB | 1 |
| Grassi, A | 1 |
| Ballardini, G | 1 |
| Mukherjee, TI | 1 |
| Pillai, V | 1 |
| Ali, SH | 1 |
| Altice, FL | 4 |
| Kamarulzaman, A | 1 |
| Wickersham, JA | 1 |
| Page, K | 3 |
| Leeman, L | 1 |
| Bishop, S | 1 |
| Cano, S | 1 |
| Bakhireva, LN | 1 |
| Li, M | 1 |
| Li, R | 1 |
| Shen, Z | 1 |
| Li, C | 1 |
| Liang, N | 1 |
| Peng, Z | 1 |
| Huang, W | 1 |
| He, C | 1 |
| Zhong, F | 1 |
| Tang, X | 1 |
| Lan, G | 1 |
| Zhou, ZR | 1 |
| Cao, YN | 1 |
| Jessop, A | 2 |
| Maurer, L | 2 |
| Gashat, M | 2 |
| Al Hajji, M | 1 |
| Xu, Y | 2 |
| Xia, Y | 1 |
| McLinden, T | 1 |
| Moodie, EEM | 1 |
| Hamelin, AM | 1 |
| Harper, S | 1 |
| Rossi, C | 1 |
| Walmsley, SL | 1 |
| Rourke, SB | 1 |
| Cooper, C | 1 |
| Klein, MB | 1 |
| Cox, J | 3 |
| Ti, L | 1 |
| Wood, E | 4 |
| Milloy, MJ | 1 |
| Nosova, E | 1 |
| DeBeck, K | 1 |
| Kerr, T | 4 |
| Hayashi, K | 1 |
| Bauerle Bass, S | 1 |
| Forry, J | 1 |
| Lozano, R | 1 |
| Domeque, N | 1 |
| Perálvarez, C | 1 |
| Torrellas, MD | 1 |
| Gonzalo, C | 1 |
| Azbel, L | 1 |
| Wegman, MP | 1 |
| Polonsky, M | 1 |
| Bachireddy, C | 1 |
| Meyer, J | 1 |
| Shumskaya, N | 1 |
| Kurmanalieva, A | 1 |
| Dvoryak, S | 1 |
| Valencia La Rosa, J | 1 |
| Ryan, P | 1 |
| Alvaro-Meca, A | 1 |
| Troya, J | 1 |
| Cuevas, G | 1 |
| Gutiérrez, J | 1 |
| Moreno, S | 1 |
| Talal, AH | 5 |
| McLeod, A | 2 |
| Andrews, P | 2 |
| Nieves-McGrath, H | 1 |
| Chen, Y | 4 |
| Reynolds, A | 1 |
| Sylvester, C | 2 |
| Dickerson, SS | 1 |
| Markatou, M | 3 |
| Brown, LS | 4 |
| Lu, J | 1 |
| Xu, X | 1 |
| Zhou, Y | 1 |
| Zhang, Z | 2 |
| Fu, G | 1 |
| Chen, G | 1 |
| Younis, IR | 1 |
| Lakota, EA | 1 |
| Volpe, DA | 1 |
| Patel, V | 1 |
| Sahajwalla, CG | 1 |
| Artenie, AA | 1 |
| Minoyan, N | 1 |
| Jacka, B | 1 |
| Høj, S | 1 |
| Jutras-Aswad, D | 1 |
| Roy, É | 2 |
| Gauvin, L | 1 |
| Zang, G | 1 |
| Bruneau, J | 1 |
| Bair, MJ | 1 |
| Huang, CF | 1 |
| Yeh, ML | 1 |
| Dai, CY | 1 |
| Chuang, WL | 1 |
| Huang, JF | 1 |
| Williams, N | 1 |
| Bossert, N | 1 |
| Jaanimägi, U | 1 |
| Roux, P | 3 |
| Morel, A | 3 |
| Wolfe, D | 1 |
| Carrieri, P | 1 |
| Ng, MH | 1 |
| Chou, JY | 1 |
| Chang, TJ | 1 |
| Lee, PC | 1 |
| Shao, WC | 1 |
| Lin, TY | 1 |
| Chen, VC | 1 |
| Gossop, M | 1 |
| Wu, Z | 6 |
| Clark, N | 1 |
| Bruce, RD | 3 |
| Moody, DE | 1 |
| Gourevitch, MN | 3 |
| Friedland, GH | 1 |
| Manan, MM | 1 |
| Ali, SM | 1 |
| Khan, MA | 1 |
| Jafarian, S | 1 |
| Hameed, MA | 1 |
| Xia, YH | 2 |
| McLaughlin, MM | 1 |
| Tucker, JD | 2 |
| Wang, Z | 2 |
| Xiao, Z | 1 |
| Mandel, JS | 1 |
| Otiashvili, D | 1 |
| Piralishvili, G | 2 |
| Sikharulidze, Z | 1 |
| Kamkamidze, G | 1 |
| Poole, S | 1 |
| Woody, GE | 1 |
| Wu, SL | 2 |
| Wang, SC | 2 |
| Tsou, HH | 2 |
| Kuo, HW | 2 |
| Liu, SW | 2 |
| Hsu, YT | 1 |
| Chang, YS | 1 |
| Liu, YL | 3 |
| Wang, C | 5 |
| Zhang, D | 1 |
| Duan, S | 2 |
| Han, J | 1 |
| Tang, RH | 2 |
| Yang, YC | 1 |
| Xiang, LF | 1 |
| Ye, RH | 1 |
| Yang, SS | 1 |
| Yang, YB | 1 |
| Long, YC | 2 |
| Li, GQ | 1 |
| Yin, MS | 1 |
| Pang, L | 3 |
| Rou, KM | 1 |
| Wu, ZY | 1 |
| He, N | 1 |
| Larios, SE | 1 |
| Masson, CL | 2 |
| Shopshire, MS | 1 |
| Hettema, J | 1 |
| McKnight, C | 2 |
| Young, C | 2 |
| Khalili, M | 1 |
| Seewald, RM | 2 |
| Min, A | 1 |
| Hengl, N | 1 |
| Sorensen, JL | 2 |
| Des Jarlais, DC | 8 |
| Wang, L | 1 |
| Wei, X | 1 |
| Wang, X | 3 |
| Li, J | 5 |
| Li, H | 1 |
| Jia, W | 1 |
| Gupta, S | 1 |
| Iudicello, JE | 1 |
| Shi, C | 1 |
| Letendre, S | 1 |
| Knight, A | 1 |
| Riggs, PK | 1 |
| Franklin, DR | 1 |
| Duarte, N | 1 |
| Jin, H | 1 |
| Hampton Atkinson, J | 1 |
| Yu, X | 1 |
| Grant, I | 1 |
| Heaton, RK | 1 |
| Marco, A | 1 |
| Gallego, C | 1 |
| Caylà, JA | 1 |
| Zhou, YB | 1 |
| Liang, S | 1 |
| Wang, QX | 1 |
| Gong, YH | 1 |
| Nie, SJ | 1 |
| Nan, L | 1 |
| Yang, AH | 1 |
| Liao, Q | 1 |
| Song, XX | 1 |
| Jiang, QW | 1 |
| Peles, E | 2 |
| Schreiber, S | 2 |
| Adelson, M | 4 |
| Chavchanidze, M | 1 |
| Gamkrelidze, I | 1 |
| Nikolaishvili, N | 1 |
| Phillips, KA | 1 |
| Epstein, DH | 2 |
| Vahabzadeh, M | 1 |
| Mezghanni, M | 1 |
| Lin, JL | 1 |
| Preston, KL | 2 |
| Nolan, S | 1 |
| Dias Lima, V | 1 |
| Fairbairn, N | 1 |
| Montaner, J | 1 |
| Grebely, J | 2 |
| Lions, C | 2 |
| Michel, L | 2 |
| Mora, M | 2 |
| Daulouède, JP | 1 |
| Marcellin, F | 2 |
| Spire, B | 3 |
| Carrieri, PM | 2 |
| Sepúlveda-Arias, JC | 1 |
| Isaza, C | 1 |
| Vélez, JP | 1 |
| Delucchi, KL | 1 |
| Tsui, JI | 2 |
| Evans, JL | 1 |
| Lum, PJ | 1 |
| Hahn, JA | 1 |
| Zhou, W | 2 |
| Zhou, S | 2 |
| Xie, N | 1 |
| Liu, P | 1 |
| Luo, L | 1 |
| Peng, J | 1 |
| Liu, M | 1 |
| Desrosiers, A | 1 |
| Schottenfeld, R | 1 |
| Chawarski, MC | 1 |
| Sullivan, SG | 2 |
| Rou, K | 4 |
| Luo, W | 4 |
| Cao, X | 5 |
| Yin, W | 3 |
| Liu, E | 2 |
| Mi, G | 1 |
| Malnick, S | 1 |
| Sheidvasser, V | 1 |
| Basevitz, A | 1 |
| Levit, S | 2 |
| Lin, CK | 1 |
| Hung, CC | 1 |
| Peng, CY | 3 |
| Chao, E | 1 |
| Lee, TS | 2 |
| Meemken, L | 1 |
| Hanhoff, N | 1 |
| Tseng, A | 1 |
| Christensen, S | 1 |
| Gillessen, A | 1 |
| Hwang, LL | 1 |
| Dai, YW | 1 |
| Liu, SC | 1 |
| Chen, AC | 1 |
| Hsiao, CF | 1 |
| Lira, MC | 1 |
| Cheng, DM | 1 |
| Winter, MR | 1 |
| Alford, DP | 1 |
| Liebschutz, JM | 1 |
| Mao, J | 1 |
| Edwards, RR | 1 |
| Samet, JH | 1 |
| Gervasoni, C | 1 |
| Peri, AM | 1 |
| Cattaneo, D | 1 |
| Baldelli, S | 1 |
| Rizzardini, G | 1 |
| Milazzo, L | 1 |
| Batchelder, AW | 1 |
| Peyser, D | 1 |
| Nahvi, S | 1 |
| Arnsten, JH | 2 |
| Maradan, G | 1 |
| Pu, L | 1 |
| Su, Y | 1 |
| Wang, G | 1 |
| Bai, J | 1 |
| Shi, CX | 1 |
| Zhao, Y | 1 |
| Ogbuagu, O | 1 |
| Friedland, G | 1 |
| Des Jarlais, D | 1 |
| Duong, HT | 1 |
| Pham Minh, K | 1 |
| Khuat, OH | 1 |
| Nham, TT | 1 |
| Arasteh, K | 1 |
| Feelemyer, J | 1 |
| Heckathorn, DD | 1 |
| Peries, M | 1 |
| Moles, JP | 1 |
| Laureillard, D | 1 |
| Nagot, N | 1 |
| Cornford, C | 1 |
| Close, H | 1 |
| Zhang, JN | 1 |
| Wang, YK | 1 |
| Jiang, Y | 1 |
| Wang, JB | 1 |
| Feng, KD | 1 |
| Zhang, ZM | 1 |
| Zhao, Q | 1 |
| Zhang, GY | 1 |
| Qiu, MF | 1 |
| Li, N | 1 |
| Wang, XW | 1 |
| Nie, YG | 1 |
| Ma, YM | 1 |
| Yang, WJ | 1 |
| Fan, PY | 1 |
| Sun, DY | 1 |
| Zhu, Q | 1 |
| Midgard, H | 1 |
| Bramness, JG | 1 |
| Skurtveit, S | 1 |
| Haukeland, JW | 1 |
| Dalgard, O | 1 |
| Cella, E | 1 |
| Kong, WH | 1 |
| Liu, MQ | 2 |
| Liu, PL | 1 |
| Ciccozzi, M | 1 |
| Salemi, M | 1 |
| Chen, X | 1 |
| Silva, MJ | 1 |
| Pereira, C | 1 |
| Loureiro, R | 1 |
| Balsa, C | 1 |
| Lopes, P | 1 |
| Água-Doce, I | 1 |
| Belo, E | 1 |
| Martins, HC | 1 |
| Coutinho, R | 2 |
| Pádua, E | 1 |
| Brown, JL | 1 |
| Gause, NK | 1 |
| Lewis, D | 1 |
| Winhusen, T | 1 |
| Wurst, FM | 1 |
| Dürsteler-MacFarland, KM | 1 |
| Auwaerter, V | 1 |
| Ergovic, S | 1 |
| Thon, N | 1 |
| Yegles, M | 1 |
| Halter, C | 1 |
| Weinmann, W | 1 |
| Wiesbeck, GA | 1 |
| Treloar, C | 3 |
| Holt, M | 1 |
| Todadze, K | 1 |
| Lezhava, G | 1 |
| Nyamathi, A | 1 |
| de Castro, V | 1 |
| McNeese-Smith, D | 1 |
| Nyamathi, K | 1 |
| Shoptaw, S | 1 |
| Marfisee, M | 1 |
| Khalilifard, F | 1 |
| Cohen, A | 1 |
| Batki, SL | 2 |
| Canfield, KM | 2 |
| Smyth, E | 2 |
| Ploutz-Snyder, R | 1 |
| Morissette, C | 1 |
| De, P | 2 |
| Tremblay, C | 1 |
| Allard, R | 1 |
| Graves, L | 1 |
| Stephenson, R | 1 |
| John-Baptiste, A | 1 |
| Varenbut, M | 1 |
| Lingley, M | 1 |
| Nedd-Roderique, T | 1 |
| Teplin, D | 1 |
| Tomlinson, G | 1 |
| Daiter, J | 1 |
| Krahn, M | 1 |
| Ryder, N | 1 |
| Cullen, W | 4 |
| Barry, J | 1 |
| Bury, G | 4 |
| Keenan, E | 1 |
| Smyth, BP | 1 |
| Pei, DE | 1 |
| Peng, JS | 1 |
| Liu, AJ | 1 |
| An, EI | 1 |
| Murray, HG | 1 |
| Tetstall, E | 1 |
| Leroi, MJ | 1 |
| Nanan, RK | 1 |
| Petoumenos, K | 1 |
| Matthews, GV | 1 |
| Haber, P | 2 |
| Marks, P | 1 |
| Lloyd, AR | 1 |
| Kaldor, JM | 1 |
| Dore, GJ | 4 |
| Cohen-Moreno, R | 2 |
| Schiff, M | 2 |
| Levitt, S | 1 |
| Bar-Hamburger, R | 1 |
| Strauss, S | 1 |
| Neumark, Y | 2 |
| Newland, J | 2 |
| Rance, J | 2 |
| Hopwood, M | 2 |
| Dolan, K | 4 |
| Teutsch, S | 1 |
| Scheuer, N | 1 |
| Levy, M | 1 |
| Rawlinson, W | 1 |
| Kaldor, J | 2 |
| Lloyd, A | 1 |
| Curth, NK | 1 |
| Hansson, LN | 1 |
| Storm, F | 1 |
| Lazarus, JV | 1 |
| Lau, EM | 1 |
| McCaughan, G | 1 |
| Torzillo, PJ | 1 |
| Vickerman, P | 2 |
| Martin, N | 1 |
| Hickman, M | 2 |
| Hao, Y | 1 |
| Sun, X | 1 |
| Gong, X | 1 |
| Li, F | 1 |
| Martinez, AD | 1 |
| Dimova, R | 1 |
| Marks, KM | 1 |
| Beeder, AB | 1 |
| Zeremski, M | 2 |
| Kreek, MJ | 3 |
| Taylor, LE | 1 |
| Bowman, SE | 1 |
| Chapman, S | 1 |
| Zaller, N | 1 |
| Stein, MD | 1 |
| Cioe, PA | 1 |
| Maynard, MA | 1 |
| McGovern, BH | 1 |
| Salimi, S | 2 |
| Nassirimanesh, B | 2 |
| Mohsenifar, S | 2 |
| Mokri, A | 2 |
| Shen, HC | 1 |
| Wu, WH | 1 |
| Huang, CW | 1 |
| Yen, MY | 3 |
| Wang, BE | 1 |
| Chuang, P | 3 |
| Shih, CY | 1 |
| Chou, YC | 1 |
| Chan, DP | 1 |
| Lee, SS | 2 |
| Lee, KC | 2 |
| Turner, KM | 1 |
| Hutchinson, S | 1 |
| Hope, V | 1 |
| Craine, N | 1 |
| Palmateer, N | 1 |
| May, M | 1 |
| Taylor, A | 2 |
| De Angelis, D | 1 |
| Cameron, S | 2 |
| Parry, J | 1 |
| Lyons, M | 1 |
| Goldberg, D | 1 |
| Allen, E | 1 |
| Saiz, PA | 1 |
| García-Portilla, MP | 1 |
| Díaz-Mesa, EM | 1 |
| Burón, P | 1 |
| Casares, MJ | 1 |
| Marina, P | 1 |
| Gutiérrez, E | 1 |
| Rados, V | 1 |
| Allsop, D | 1 |
| Sharma, A | 1 |
| Cohen, HW | 1 |
| Freeman, R | 1 |
| Santoro, N | 1 |
| Schoenbaum, EE | 1 |
| Bini, EJ | 1 |
| Kritz, S | 2 |
| Robinson, J | 1 |
| Calsyn, D | 1 |
| Alderson, D | 1 |
| Tracy, K | 1 |
| McAuliffe, P | 1 |
| Smith, C | 1 |
| Rotrosen, J | 1 |
| Berg, KM | 1 |
| Li, X | 1 |
| Hidalgo, J | 1 |
| Deren, S | 1 |
| Kang, SY | 1 |
| Mino, M | 1 |
| Hser, Y | 1 |
| Chang, YJ | 1 |
| Evans, E | 1 |
| Morse, DS | 1 |
| Williams, GC | 1 |
| Eiserman, J | 1 |
| Acosta, A | 1 |
| Gote, C | 1 |
| Lim, JK | 1 |
| Xie, B | 1 |
| Dimova, RB | 1 |
| Seewald, R | 1 |
| Peterson, RH | 1 |
| Lee, HY | 1 |
| Li, JH | 1 |
| Wu, LT | 1 |
| Wu, JS | 1 |
| Yen, CF | 1 |
| Tang, HP | 1 |
| White, DL | 1 |
| Hashmi, A | 1 |
| Ramsey, DJ | 1 |
| Kuzniarek, J | 1 |
| Tavakoli-Tabasi, S | 1 |
| El-Serag, HB | 1 |
| Zhuang, X | 2 |
| Liang, Y | 2 |
| Chow, EP | 2 |
| Wang, Y | 2 |
| Wilson, DP | 2 |
| Yen, YF | 2 |
| Rodwell, TC | 1 |
| Hsu, YH | 1 |
| Li, LH | 2 |
| Su, LW | 2 |
| Yang, YH | 1 |
| Jiang, XR | 2 |
| Fang, YC | 1 |
| Garfein, RS | 1 |
| Allen, EJ | 1 |
| Palmateer, NE | 1 |
| Hutchinson, SJ | 1 |
| Goldberg, DJ | 1 |
| Wu, F | 1 |
| Jiang, H | 1 |
| Zhang, R | 1 |
| Hser, YI | 1 |
| Tan, L | 1 |
| Li, Y | 1 |
| Zhang, Y | 1 |
| Zhou, D | 1 |
| Liu, T | 1 |
| Hao, W | 1 |
| Li, D | 1 |
| Chu, P | 1 |
| Yang, Y | 1 |
| Li, S | 1 |
| Ruan, Y | 1 |
| Liu, Z | 1 |
| Lu, L | 2 |
| Jia, Z | 1 |
| McNicholas, LF | 1 |
| Holbrook, AM | 1 |
| O'Grady, KE | 1 |
| Jones, HE | 1 |
| Coyle, MG | 1 |
| Martin, PR | 1 |
| Heil, SH | 1 |
| Stine, SM | 1 |
| Kaltenbach, K | 1 |
| Poundstone, KE | 1 |
| Harris, M | 1 |
| Rhodes, T | 1 |
| Deng, CY | 1 |
| Piccolo, P | 1 |
| Borg, L | 1 |
| Lin, A | 1 |
| Melia, D | 1 |
| Ho, A | 1 |
| Sibbald, B | 1 |
| Clarke, SM | 2 |
| Mulcahy, FM | 2 |
| Esteban, J | 1 |
| Gimeno, C | 1 |
| Aragonés, A | 1 |
| Barril, J | 1 |
| Pellín, Mde L | 1 |
| Wilczek, H | 1 |
| Urbánek, P | 1 |
| Strauss, SM | 5 |
| Astone, J | 1 |
| Vassilev, ZP | 1 |
| Hagan, H | 6 |
| Perry, M | 1 |
| Chew-Graham, C | 1 |
| Di Martini, A | 1 |
| Weinrieb, R | 1 |
| Weinrieb, RM | 1 |
| Barnett, R | 1 |
| Lynch, KG | 1 |
| DePiano, M | 1 |
| Atanda, A | 1 |
| Olthoff, KM | 1 |
| Astone, JM | 3 |
| Jarlais, DD | 1 |
| Haig, T | 1 |
| Sheerin, IG | 1 |
| Green, FT | 1 |
| Sellman, JD | 1 |
| Baklan, Z | 1 |
| Gorisek, JR | 1 |
| Poljak, M | 1 |
| Pisec, A | 1 |
| Lançon, C | 1 |
| Jaquet, I | 1 |
| Labrune, N | 1 |
| Bartolo, K | 1 |
| De Stopeleire, C | 1 |
| Auquier, P | 1 |
| Hallinan, R | 3 |
| Byrne, A | 3 |
| Amin, J | 2 |
| Sylvestre, DL | 3 |
| Soloway, I | 1 |
| Backmund, M | 2 |
| Reimer, J | 1 |
| Meyer, K | 1 |
| Gerlach, JT | 1 |
| Zachoval, R | 1 |
| Walley, AY | 1 |
| White, MC | 1 |
| Kushel, MB | 1 |
| Song, YS | 1 |
| Tulsky, JP | 1 |
| Kelly, Y | 3 |
| Stanley, J | 3 |
| Langton, D | 3 |
| Dolan, KA | 1 |
| Shearer, J | 2 |
| White, B | 1 |
| Zhou, J | 1 |
| Wodak, AD | 1 |
| Wittchen, HU | 1 |
| Apelt, SM | 1 |
| Bühringer, G | 1 |
| Gastpar, M | 1 |
| Gölz, J | 1 |
| Kraus, MR | 1 |
| Tretter, F | 1 |
| Klotsche, J | 1 |
| Siegert, J | 1 |
| Pittrow, D | 1 |
| Soyka, M | 1 |
| Farley, J | 1 |
| Vasdev, S | 1 |
| Fischer, B | 1 |
| Haydon, E | 1 |
| Rehm, J | 1 |
| Farley, TA | 1 |
| Clements, BJ | 1 |
| Rich, JD | 1 |
| McKenzie, M | 1 |
| Shield, DC | 1 |
| Wolf, FA | 1 |
| Key, RG | 1 |
| Poshkus, M | 1 |
| Clarke, J | 1 |
| Graham, CH | 1 |
| Meechan, JG | 1 |
| McCance-Katz, EF | 1 |
| Warren, E | 1 |
| Viney, R | 1 |
| Shanahan, M | 1 |
| Wodak, A | 1 |
| Palepu, A | 1 |
| Tyndall, MW | 1 |
| Joy, R | 1 |
| Press, N | 1 |
| Hogg, RS | 1 |
| Montaner, JS | 1 |
| Chu, M | 1 |
| Madray, C | 1 |
| Lu, GH | 1 |
| Wang, QY | 1 |
| Xu, H | 1 |
| Zhu, M | 1 |
| McCoy, CB | 1 |
| Gelkopf, M | 2 |
| Weizman, T | 1 |
| Melamed, Y | 1 |
| Bleich, A | 2 |
| March, JC | 1 |
| Oviedo-Joekes, E | 1 |
| Perea-Milla, E | 1 |
| Carrasco, F | 1 |
| Préau, M | 1 |
| Protopopescu, C | 1 |
| Dellamonica, P | 1 |
| Poizot-Martin, I | 1 |
| Villes, V | 1 |
| Carrieri, MP | 1 |
| Staines, A | 1 |
| Jürgens, R | 1 |
| Betteridge, G | 1 |
| Bonnet, N | 1 |
| Munoz-Plaza, CE | 1 |
| Astone-Twerwll, JM | 1 |
| Hancock, MM | 1 |
| Prosser, CC | 1 |
| Ransibrahmanakul, K | 1 |
| Lester, L | 1 |
| Craemer, E | 1 |
| Bourgeois, JA | 1 |
| Rossaro, L | 1 |
| Bannan, N | 1 |
| Rooney, S | 1 |
| O'connor, J | 1 |
| Semba, RD | 1 |
| Ricketts, EP | 1 |
| Mehta, SF | 1 |
| Kirk, GD | 1 |
| Latkin, C | 1 |
| Galai, N | 1 |
| Vlahov, D | 1 |
| Okon, T | 1 |
| Cofrancesco, J | 1 |
| Brown, TT | 1 |
| Luo, RF | 1 |
| John, M | 1 |
| Stewart, KJ | 1 |
| Dobs, AS | 1 |
| Miller, CL | 1 |
| Strathdee, SA | 1 |
| Li, K | 1 |
| van Beek, I | 1 |
| Van Den Berg, C | 1 |
| Smit, C | 1 |
| Van Brussel, G | 1 |
| Prins, M | 1 |
| Novick, DM | 1 |
| Boivin, JF | 1 |
| Platt, RW | 1 |
| Jolly, AM | 1 |
| Michels, II | 1 |
| Fang, YX | 1 |
| Zhao, D | 1 |
| Zhao, LY | 1 |
| Pelet, A | 1 |
| Doll, S | 1 |
| Huissoud, T | 1 |
| Resplendino, J | 1 |
| Besson, J | 1 |
| Favrat, B | 1 |
| Willner-Reid, J | 1 |
| Belendiuk, KA | 1 |
| Schmittner, J | 1 |
| Lim, WW | 1 |
| Aitken, CK | 1 |
| Higgs, PG | 1 |
| Hellard, ME | 1 |
| Chetwynd, J | 1 |
| Brunton, C | 1 |
| Blank, M | 1 |
| Plumridge, E | 1 |
| Baldwin, D | 1 |
| Crofts, N | 2 |
| Hopper, JL | 1 |
| Bowden, DS | 1 |
| Breschkin, AM | 1 |
| Milner, R | 1 |
| Locarnini, SA | 1 |
| Van Ameijden, EJ | 1 |
| Van den Hoek, JA | 1 |
| Mientjes, GH | 1 |
| Coutinho, RA | 1 |
| Selvey, LA | 1 |
| Denton, M | 1 |
| Plant, AJ | 1 |
| Nigro, L | 1 |
| Oman, K | 1 |
| Stevenson, E | 1 |
| Sherman, J | 1 |
| Lozano Polo, JL | 1 |
| Gutiérrez Mora, E | 1 |
| Martínez Pérez, V | 1 |
| Santamaría Gutiérrez, J | 1 |
| Vada Sánchez, J | 1 |
| Vallejo Correas, JA | 1 |
| Salter, A | 1 |
| Solomon, PJ | 1 |
| Stein, GL | 1 |
| Fleischman, AR | 1 |
| Broers, B | 1 |
| Junet, C | 1 |
| Bourquin, M | 1 |
| Déglon, JJ | 2 |
| Perrin, L | 1 |
| Hirschel, B | 2 |
| Schmidt, V | 1 |
| Hayward, R | 1 |
| Bodner, G | 1 |
| Ebert, FW | 1 |
| Thiede, H | 1 |
| Murrill, CS | 1 |
| Zylberberg, H | 1 |
| Fontaine, H | 1 |
| Corréas, JM | 1 |
| Carnot, F | 1 |
| Bréchot, C | 1 |
| Pol, S | 1 |
| Cayol, V | 1 |
| Corcos, M | 1 |
| Clervoy, P | 1 |
| Speranza, M | 1 |
| Stephenson, J | 1 |
| Koch, M | 1 |
| Banys, P | 1 |
| McCarthy, JJ | 1 |
| Flynn, N | 1 |
| Tennant, F | 1 |
| Carter, H | 1 |
| Robinson, G | 1 |
| Hanlon, C | 1 |
| Hailwood, C | 1 |
| Massarotto, A | 1 |
| Ladewig, D | 1 |
| Steffen, T | 1 |
| Blättler, R | 1 |
| Gutzwiller, F | 1 |
| Zwahlen, M | 1 |
| Lines, R | 1 |
| Chamot, E | 1 |
| de Saussure, P | 1 |
| Perrin, LH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Implementation and Evaluation of Care Coordination in Linkage to Care for Hepatitis C Following Release From New York City Jails[NCT04036760] | 105 participants (Actual) | Observational | 2015-05-31 | Completed | |||
| Reducing Hepatitis C Virus (HCV)/Human Immunodeficient Virus (HIV) Risk Behaviors Among Injection Drug Users in China[NCT01647191] | 240 participants (Actual) | Interventional | 2011-07-01 | Completed | |||
| Reaching mEthadone Users Attending Community pHarmacies With HCV[NCT03935906] | 210 participants (Actual) | Interventional | 2019-10-08 | Completed | |||
| Targeted Focus Groups Discussions (FGDs) and Cross-sectional Questionnaire to Address Questions Regarding Telemedicine Concept and Knowledge, and Social Media Usage Among People Who Inject Drugs (PWID) in Greece[NCT05794984] | 220 participants (Anticipated) | Observational | 2023-05-01 | Active, not recruiting | |||
| Suboxone and Methadone for HIV Risk Reduction in Subutex Injectors[NCT01131273] | Phase 3 | 68 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| Initialization of Methadone in Primary Care; a Randomized Intervention Research for Preventing HCV Transmission Practices. ANRS Methaville[NCT00657397] | Phase 3 | 197 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Prospective, Single Arm, Open-label 96 Week Observational Trial of the Tolerability, Adherence and Efficacy of a Dolutegravir/Abacavir/Lamivudine Single Tablet Regimen in HIV-1 Antibody Positive People Living With HIV With a History of Injection Drug Us[NCT02659761] | Phase 4 | 50 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | ||
| [NCT01059747] | 500 participants (Anticipated) | Observational | 2008-12-31 | Recruiting | |||
| Feasibility of an Interventional Project to Reduce HIV Incidence Among People Who Inject Drugs in Haiphong, Viet Nam[NCT02573948] | 603 participants (Actual) | Observational | 2014-09-30 | Completed | |||
| DRIVE (DRug Use and Infections in ViEtnam) Project : Ending the HIV Epidemic Among Persons Who Inject Drugs in Hai Phong, Viet Nam[NCT03526939] | 5,546 participants (Actual) | Observational | 2016-10-17 | Completed | |||
| Towards Ending HCV Infection Among Active Drug Users: a Community-based Intervention in Montpellier.[NCT04008927] | 554 participants (Actual) | Interventional | 2020-09-18 | Completed | |||
| Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam[NCT03537196] | Phase 4 | 979 participants (Actual) | Interventional | 2018-11-13 | Completed | ||
| Directly Observed Hepatitis C Treatment in Methadone Clinics[NCT01442311] | 80 participants (Actual) | Interventional | 2007-10-31 | Completed | |||
| Maternal Opioid Treatment: Human Experimental Research[NCT00271219] | Phase 3 | 175 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| A Prospective Cohort Study Comparing the Effectiveness of Zepatier for the Treatment of Hepatitis C in an Academic Center Population to People Who Inject Drugs (PWIDs) in a Safety Net Clinic Setting Engaged in Either a Medication Assisted Therapy (MAT) or[NCT03093415] | Phase 4 | 100 participants (Actual) | Interventional | 2017-05-30 | Completed | ||
| Oral Ketamine for Control of Chronic Pain in Children[NCT01369680] | Phase 1 | 12 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| [NCT00292123] | Phase 1 | 200 participants (Actual) | Interventional | 1999-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of new HCV infection among HCV negative (at RDS) cohort participants over 1 year period (NCT02573948)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| HCV Negative Cohort Participants | 18 |
HIV incidence was calculated by 100person/year. With zero conversion, we choose 2.5% unilateral confidence interval. (NCT02573948)
Timeframe: 52 weeks
| Intervention | infections per 100 person-years (Number) |
|---|---|
| HIV Negative Cohort Participants | 0 |
Number of new HIV infection among HIV negative (at RDS) cohort participants over 1 year period. (NCT02573948)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| HIV Negative Cohort Participants | 0 |
The HCV incidence was calculated by 100person/year (NCT02573948)
Timeframe: 52 weeks
| Intervention | infections per 100 person-years (Number) |
|---|---|
| HCV Negative Cohort Participants | 19.4 |
Number of participants who were followed up and not lost to follow-up after enrolment into cohort. (NCT02573948)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| PWID Cohort | 194 |
(NCT00271219)
Timeframe: birth
| Intervention | cm (Mean) |
|---|---|
| A Methadone | 33.0 |
| B Buprenorphine | 33.8 |
(NCT00271219)
Timeframe: delivery until hospital discharge (min=2 days, max=79 days)
| Intervention | days (Mean) |
|---|---|
| A Methadone | 17.5 |
| B Buprenorphine | 10.0 |
NAS was measured with the MOTHER NAS scale, which includes 28 items, 19 of which are used for scoring and medication decisions. Scores can range from 0 to 42, with higher scores indicating more severe withdrawal. (NCT00271219)
Timeframe: minimum twice daily from birth until NAS no longer measured (min=10 days)
| Intervention | Score on the scale (Mean) |
|---|---|
| A Methadone | 12.8 |
| B Buprenorphine | 11.0 |
(NCT00271219)
Timeframe: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)
| Intervention | percentage of HIV risk behaviors (Number) |
|---|---|
| A Methadone | NA |
| B Buprenorphine | NA |
Pregnant women maintained on an opioid agonist medication may require upward adjustment to their medication during the course of pregnant. The Dose Adequacy Measure represented a recordation of dosing adjustments during the course of the study. (NCT00271219)
Timeframe: from study entry until discontinuation or delivery (min=29 days, max=239 days)
| Intervention | dose increase per trimester (Number) |
|---|---|
| A Methadone | NA |
| B Buprenorphine | NA |
The Addiction Severity Index is a structured clinical interview that assesses problem severity in 7 areas of functioning: alcohol use, drug use, medical, legal, employment, psychosocial, and psychiatric status. Each area of functioning yields a composite scale score between 0 and 1, with higher scores indicating greater problem severity in that area. Only the psychosocial index was examined in this study. (NCT00271219)
Timeframe: at delivery
| Intervention | Score on the scale (Mean) |
|---|---|
| Methadone | .014 |
| Buprenorphine | .088 |
(NCT00271219)
Timeframe: monthly from study entry until discontinuation or delivery (min=29 days, max=239 days)
| Intervention | percentage of drug use (Number) |
|---|---|
| A Methadone | NA |
| B Buprenorphine | NA |
Neonatal abstinence syndrome (NAS) characterized by hyperirritability of the central nervous system and dysfunction in the autonomic nervous system, gastrointestinal tract, and respiratory system.11 When left untreated, NAS can result in serious illness (e.g., diarrhea, feeding difficulties, weight loss, and seizures) and death. (NCT00271219)
Timeframe: From birth until hospital discharge (min=4 days, max=10, depending on site)
| Intervention | participants (Number) |
|---|---|
| A Methadone | 41 |
| B Buprenorphine | 27 |
Total amount in mg (NCT00271219)
Timeframe: Start of NAS treatment until discontinuation of NAS treatment (min=0 days, max=76 days)
| Intervention | mg (Mean) |
|---|---|
| A Methadone | 10.4 |
| B Buprenorphine | 1.1 |
"Baseline neurocognitive testing will be done before study drug is given. Subjects will be reassessed for any changes in neurocognitive scores at end of dosing (week 2) and at three weeks off study drug (week 14). Significant changes were measured at week 14 compared to baseline. Week 2 was measured to inform future studies.~The neurocognitive scores are standardized scores with a mean of 100; low scores correlate with low neurocognitive function, while high scores correlate with high function. A significant change is defined as greater than or equal to 10% decrease in scores." (NCT01369680)
Timeframe: At 14 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 0 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 0 |
| Ketamine 1.5 mg/kg/Dose | 0 |
Pharmacokinetic testing will be done during chronic ketamine administration on subjects consenting to additional testing one week into study drug administration. This is to further describe the activity of ketamine in the blood of children when administered chronically and to enable comparison of any clinical effect or toxicity with steady state levels of ketamine in children. (NCT01369680)
Timeframe: At week 1
| Intervention | ng/mL (Mean) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 37.5 |
| Ketamine 0.5 mg/kg/Dose | 135 |
| Ketamine 1 mg/kg/Dose | 250 |
According to CTCae any dose causing grade 2 or worse toxicity will be an untolerated dose. Tolerability is defined as ability to take the medication for 2 weeks without having a grade 2 or worse toxicity. (NCT01369680)
Timeframe: Up to 2 weeks
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 3 |
| Ketamine 1 mg/kg/Dose | 3 |
| Ketamine 1.5 mg/kg/Dose | 1 |
"Subjects will be assessed for clinically significant change in pain scores during and after study drug administration. Significant change in pain scores were determined at week 2, though week 14 scores were collected as well.~Participants with a 2 point (or greater) decrease in pain scores compared to baseline were considered to have responded. The NRS scale was used, the scale ranges from 0-10, with 10 being the most pain." (NCT01369680)
Timeframe: Week 2
| Intervention | participants (Number) |
|---|---|
| Ketamine 0.25 mg/kg/Dose | 3 |
| Ketamine 0.5 mg/kg/Dose | 0 |
| Ketamine 1 mg/kg/Dose | 2 |
| Ketamine 1.5 mg/kg/Dose | 0 |
15 reviews available for methadone and Hepatitis C
| Article | Year |
|---|---|
Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned.
Topics: Analgesics, Opioid; Antiviral Agents; Cytochrome P-450 CYP2B6; Drug Interactions; Hepatitis C; HIV I | 2019 |
A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice.
Topics: Acquired Immunodeficiency Syndrome; Analgesics, Opioid; Anti-Retroviral Agents; Buprenorphine; Drug | 2013 |
Review on the demographic and social impact of methadone-medication therapy on Malaysian patients.
Topics: Adult; Cross-Sectional Studies; Employment; Female; Hepatitis C; HIV Infections; Humans; Malaysia; M | 2013 |
Drug-Drug Interactions With Antiviral Agents in People Who Inject Drugs Requiring Substitution Therapy.
Topics: Analgesics, Opioid; Antiviral Agents; Coinfection; Drug Interactions; Hepatitis C; HIV Infections; H | 2015 |
Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.
Topics: Animals; Antiviral Agents; Buprenorphine; Drug Interactions; Hepatitis C; Humans; Methadone; Opioid- | 2016 |
The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence.
Topics: Adult; Disease Transmission, Infectious; Epidemiologic Methods; Female; Harm Reduction; Hepatitis C; | 2011 |
HIV and HCV prevalence among entrants to methadone maintenance treatment clinics in China: a systematic review and meta-analysis.
Topics: China; Coinfection; Hepatitis C; HIV Infections; Methadone; Opiate Substitution Treatment; Prevalenc | 2012 |
Risk factors associated with HIV/HCV infection among entrants in methadone maintenance treatment clinics in China: a systematic review and meta-analysis.
Topics: Adult; Age Factors; China; Female; Hepatitis C; HIV Infections; Humans; Male; Methadone; Narcotics; | 2012 |
Hepatitis C virus infection and injection drug users: prevention, risk factors, and treatment.
Topics: Adult; Delivery of Health Care; Female; Genotype; Germany; Health Planning Guidelines; Hepatitis C; | 2005 |
Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Buprenorphine; Drug Evaluation; Drug | 2005 |
Prisoners who inject drugs: public health and human rights imperatives.
Topics: AIDS Serodiagnosis; Global Health; Hepatitis C; HIV Infections; Human Rights; Humans; International | 2005 |
Ketamine: an introduction for the pain and palliative medicine physician.
Topics: Adult; Amines; Analgesics; Analgesics, Opioid; Central Nervous System; Cryoglobulinemia; Cyclohexane | 2007 |
Comparison of drug abuse in Germany and China.
Topics: Acquired Immunodeficiency Syndrome; China; Drug and Narcotic Control; Geography; Germany; Hepatitis | 2007 |
Antiretroviral therapy for drug users.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Drug Therapy, Combination | 2000 |
[Pregnancy and drug abuse: current situation and therapeutic strategies].
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Female; Fetal Growth Retardation; Hepatit | 2000 |
22 trials available for methadone and Hepatitis C
| Article | Year |
|---|---|
Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
Topics: Analgesics, Opioid; Buprenorphine; Delayed-Action Preparations; Hepatitis C; HIV Infections; Humans; | 2022 |
Linkage to hepatitis C care after incarceration in jail: a prospective, single arm clinical trial.
Topics: Adult; Community Health Services; Continuity of Patient Care; Female; Hepatitis C; Hispanic or Latin | 2019 |
DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China.
Topics: Adult; Awareness; China; Cluster Analysis; Drug Users; Efficiency, Organizational; Female; Health Kn | 2019 |
Topics: Antiviral Agents; Australasia; Australia; Drug Users; Europe; Hepacivirus; Hepatitis C; Hepatitis C, | 2020 |
Evaluation of a hepatitis C education intervention with clients enrolled in methadone maintenance and needle/syringe programs in Malaysia.
Topics: Adult; Female; Health Education; Health Knowledge, Attitudes, Practice; Hepatitis C; Humans; Malaysi | 2017 |
The impact of methadone maintenance therapy on access to regular physician care regarding hepatitis C among people who inject drugs.
Topics: Adolescent; Adult; British Columbia; Delivery of Health Care; Female; Hepatitis C; Humans; Male; Met | 2018 |
Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
Topics: Adult; Buprenorphine; Female; Georgia (Republic); Hepatitis C; HIV Infections; Humans; Male; Methado | 2013 |
Education and counseling in the methadone treatment setting improves knowledge of viral hepatitis.
Topics: Adult; Counseling; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Hepatitis A; He | 2014 |
Factors associated with HCV risk practices in methadone-maintained patients: the importance of considering the couple in prevention interventions.
Topics: Adult; Confidence Intervals; Feasibility Studies; Female; Hepatitis C; Humans; Logistic Models; Male | 2014 |
Viral hepatitis among drug users in methadone maintenance: associated factors, vaccination outcomes, and interventions.
Topics: Adult; Aged; Female; Hepatitis A; Hepatitis B; Hepatitis C; Humans; Male; Methadone; Middle Aged; Ne | 2014 |
Suicidal risk among patients enrolled in methadone maintenance treatment: HCV status and implications for suicide prevention (ANRS Methaville).
Topics: Adult; Analgesics, Opioid; Female; Food Assistance; Hepacivirus; Hepatitis C; Humans; Male; Methadon | 2015 |
Factors associated with uptake of treatment for recent hepatitis C virus infection in a predominantly injecting drug user cohort: The ATAHC Study.
Topics: Acute Disease; Adult; Antiviral Agents; Australia; Cohort Studies; Female; Hepacivirus; Hepatitis C; | 2010 |
Rationale and design of a randomized controlled trial of directly observed hepatitis C treatment delivered in methadone clinics.
Topics: Adult; Antiviral Agents; Directly Observed Therapy; Drug Therapy, Combination; Female; Hepatitis C; | 2011 |
Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.
Topics: Adult; Antiviral Agents; Directly Observed Therapy; Female; Hepacivirus; Hepatitis C; Humans; Interf | 2012 |
Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication.
Topics: Adolescent; Adult; Analgesics, Opioid; Buprenorphine; Female; gamma-Glutamyltransferase; Hepatitis C | 2012 |
Randomized controlled trial proves effectiveness of methadone maintenance treatment in prison.
Topics: Canada; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Incidence; Methadone; New South Wale | 2003 |
Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection.
Topics: Adult; Cohort Studies; Communicable Diseases; Follow-Up Studies; Hepatitis C; Heroin Dependence; HIV | 2005 |
Value for money in drug treatment: economic evaluation of prison methadone.
Topics: Costs and Cost Analysis; Health Expenditures; Hepatitis C; Heroin Dependence; HIV Infections; Humans | 2006 |
Controlled trial of prescribed heroin in the treatment of opioid addiction.
Topics: Adult; Counseling; Drug Administration Schedule; Drug Prescriptions; Female; Health Status; Hepatiti | 2006 |
Hepatitis C infection among injecting drug users in general practice: a cluster randomised controlled trial of clinical guidelines' implementation.
Topics: Adult; Cluster Analysis; Family Practice; Female; Follow-Up Studies; Hepatitis C; Humans; Male; Meth | 2006 |
Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore.
Topics: Adult; Baltimore; Demography; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Methad | 2007 |
[Effect of methadone or naltrexone on the course of transaminases in parenteral drug users with hepatitis C virus infection].
Topics: Adult; Female; Hepatitis C; Humans; Liver; Male; Methadone; Middle Aged; Naltrexone; Narcotic Antago | 1997 |
194 other studies available for methadone and Hepatitis C
| Article | Year |
|---|---|
A 35-year follow-up study of patients admitted to methadone treatment between 1982-1984 in Asturias, Spain.
Topics: Female; Follow-Up Studies; Hepatitis B; Hepatitis C; Heroin; Heroin Dependence; HIV Seropositivity; | 2023 |
Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; | 2022 |
Methadone Maintenance Treatment for Opioid Dependents: a Retrospective Study.
Topics: Adult; Analgesics, Opioid; Hepatitis C; Heroin; Humans; Illicit Drugs; Methadone; Methamphetamine; M | 2022 |
Access to needles and syringes and methadone maintenance therapy among people who inject drugs in Yangon, Myanmar: a qualitative study.
Topics: Drug Users; Hepatitis C; HIV Infections; Humans; Methadone; Myanmar; Substance Abuse, Intravenous; S | 2022 |
A new collaborative care approach toward hepatitis C elimination in marginalized populations.
Topics: Antiviral Agents; Hepacivirus; Hepatitis C; HIV Infections; Humans; Methadone; Substance Abuse, Intr | 2023 |
[Aging in a methadone maintenance program. A perspective from the framework of social determinants of health].
Topics: Adult; Age of Onset; Aging; Comorbidity; Female; Hepatitis C; HIV Infections; Humans; Life Expectanc | 2019 |
Optimising opioid substitution therapy in the prison environment.
Topics: Age Factors; Buprenorphine; Comorbidity; Continuity of Patient Care; Delayed-Action Preparations; Dr | 2019 |
Perceptions of Barriers and Benefits of HCV Treatment and Correlates to Treatment Intention in Methadone Patients.
Topics: Adaptation, Psychological; Adult; Aged; Attitude to Health; Female; Hepatitis C; Humans; Intention; | 2019 |
Hepatitis C Virus Treatment Status and Barriers among Patients in Methadone Maintenance Treatment Clinics in Guangdong Province, China: A Cross-Sectional, Observational Study.
Topics: Adult; Antiviral Agents; China; Cross-Sectional Studies; Female; Hepacivirus; Hepatitis C; Humans; M | 2019 |
"Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy.
Topics: Decision Support Techniques; Female; Health Knowledge, Attitudes, Practice; Hepacivirus; Hepatitis C | 2020 |
The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Topics: Adult; Analgesics, Opioid; British Columbia; Buprenorphine; Female; Hepatitis C; Humans; Ill-Housed | 2020 |
Effectiveness of the methadone programme in the treatment of patients on a mephedrone binge and dependent on heroin: a retrospective study, 2010-19.
Topics: Adult; Amphetamine-Related Disorders; Comorbidity; Cross-Sectional Studies; Female; Hepatitis C; Her | 2020 |
Linkage to care strategy for the micro-elimination of hepatitis C among parenteral drug users on methadone replacement therapy in Gipuzkoa.
Topics: Antiviral Agents; Drug Users; Hepacivirus; Hepatitis C; Humans; Methadone; Opiate Substitution Treat | 2020 |
Hepatitis C Virus (HCV) Care Continuum Outcomes and HCV Community Viral Loads Among Patients in an Opioid Treatment Program.
Topics: Adolescent; Adult; Aged; Continuity of Patient Care; Endemic Diseases; Female; Health Services Needs | 2020 |
Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City.
Topics: Adolescent; Adult; Aged; Female; Hepacivirus; Hepatitis C; Humans; Incidence; Male; Methadone; Middl | 2020 |
ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Hepa | 2020 |
Experience with viral hepatitis C treatment among people who inject drugs and participate in a methadone substitution treatment program.
Topics: Antiviral Agents; Czech Republic; Hepatitis C; Humans; Methadone; Opiate Substitution Treatment; Pha | 2021 |
Reduced mortality in patients with extended duration of methadone maintenance treatment: a five-year retrospective nationwide study.
Topics: Cohort Studies; Female; Hepatitis C; Humans; Male; Methadone; Opiate Substitution Treatment; Retrosp | 2023 |
Hepatitis C treatment uptake among patients who have received methadone substitution treatment in the Republic of Georgia.
Topics: Antiviral Agents; Georgia; Georgia (Republic); Hepatitis C; Humans; Methadone; Retrospective Studies | 2021 |
Seroprevalence of hepatitis B virus infection, anti-HCV antibodies and HIV and knowledge among people who use drugs attending methadone therapy clinic in Tanzania; a cross-sectional study.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Cross-Sectional Studies; Drug Users; Female; Health K | 2021 |
HIV And HCV infection among opiate-dependent patients and methadone doses: the PROTEUS study.
Topics: Adult; Analgesics, Opioid; Anti-Retroviral Agents; Coinfection; Comorbidity; Dose-Response Relations | 2017 |
Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study.
Topics: Buprenorphine; Cost-Benefit Analysis; Crime; Health Services; Hepatitis C; HIV Infections; Humans; M | 2017 |
The impact of HCV therapy in a high HIV-HCV prevalence population: A modeling study on people who inject drugs in Ho Chi Minh City, Vietnam.
Topics: Anti-Retroviral Agents; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Likelihood Functio | 2017 |
Hepatitis C in injection drug users: It is time to treat.
Topics: Antiviral Agents; Buprenorphine; Drug Users; Hepatitis C; Humans; Interdisciplinary Communication; L | 2017 |
Hepatitis C Cascade of Care Among Pregnant Women on Opioid Agonist Pharmacotherapy Attending a Comprehensive Prenatal Program.
Topics: Adult; Analgesics, Opioid; Female; Hepacivirus; Hepatitis C; Humans; Mass Screening; Methadone; Mexi | 2017 |
Trends and factors in human immunodeficiency virus and/or hepatitis C virus testing and infection among injection drug users newly entering methadone maintenance treatment in Guangdong Province, China 2006-2013: a consecutive cross sectional study.
Topics: Adolescent; Adult; China; Coinfection; Cross-Sectional Studies; Female; Hepatitis C; Hepatitis C Ant | 2017 |
Spatial distribution of HIV, HCV, and co-infections among drug users in the southwestern border areas of China (2004-2014): a cohort study of a national methadone maintenance treatment program.
Topics: Adult; China; Cohort Studies; Coinfection; Drug Users; Female; Hepatitis C; HIV Infections; Humans; | 2017 |
Hepatitis C infection, related services, and barriers to HCV treatment among drug users in methadone maintenance treatment (MMT) clinics in Shanghai, China.
Topics: Adult; Alcoholism; Analgesics, Opioid; China; Drug Users; Female; Health Knowledge, Attitudes, Pract | 2017 |
Mapping the Barriers and Facilitators of HCV Treatment Initiation in Methadone Maintenance Therapy Patients: Implications for Intervention Development.
Topics: Adult; Aged; Female; Health Care Surveys; Health Services Accessibility; Hepatitis C; Humans; Male; | 2018 |
Strategies to control HIV and HCV in methadone maintenance treatment in Guangdong Province, China: a system dynamic modeling study.
Topics: China; Cross-Sectional Studies; Hepatitis C; HIV Infections; Humans; Methadone; Models, Biological; | 2018 |
Methadone treatment, severe food insecurity, and HIV-HCV co-infection: A propensity score matching analysis.
Topics: Adult; Analgesics, Opioid; Canada; Cohort Studies; Coinfection; Female; Food Supply; Hepatitis C; HI | 2018 |
Take Charge, Get Cured: The development and user testing of a culturally targeted mHealth decision tool on HCV treatment initiation for methadone patients.
Topics: Adult; Decision Making; Drug Users; Hepatitis C; Humans; Male; Methadone; Middle Aged; Opiate Substi | 2018 |
Mortality rate in patients on methadone treatment and infected with the human immunodeficiency virus and/or the hepatitis C virus.
Topics: Adult; Female; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Middle Aged; | 2019 |
Drug injection within prison in Kyrgyzstan: elevated HIV risk and implications for scaling up opioid agonist treatments.
Topics: Adult; Female; Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Kyrgyzstan; Male; | 2018 |
HCV seroconversion in a cohort of people who use drugs followed in a mobile harm reduction unit in Madrid: Breaking barriers for HCV elimination.
Topics: Adult; Cohort Studies; Female; Harm Reduction; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; Hum | 2018 |
Patient Reaction to Telemedicine for Clinical Management of Hepatitis C Virus Integrated into an Opioid Treatment Program.
Topics: Adult; Antiviral Agents; Combined Modality Therapy; Disease Management; Female; Hepatitis C; Humans; | 2019 |
Integrated, Co-located, Telemedicine-based Treatment Approaches for Hepatitis C Virus Management in Opioid Use Disorder Patients on Methadone.
Topics: Adult; Aged; Analgesics, Opioid; Antiviral Agents; Disease Management; Female; Hepatitis C; Humans; | 2019 |
Hepatitis C virus genotype diversity and distribution among methadone maintenance treatment patients in Jiangsu, China.
Topics: Adult; China; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; | 2019 |
Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs.
Topics: Adult; Buprenorphine; Cohort Studies; Disease Transmission, Infectious; Drug Users; Female; Hepatiti | 2019 |
Integrated care for methadone maintenance patients with hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Cohort Studies; Delivery of Health Care, Integrated; Female; Follow-Up Stud | 2019 |
Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection.
Topics: Adult; Cross-Sectional Studies; Female; Hepatitis C; Humans; Male; Methadone; Middle Aged; Opiate Su | 2019 |
Methadone in primary care in France: Using evidence for action against hepatitis C.
Topics: France; Hepatitis C; Humans; Methadone; Opiate Substitution Treatment; Opioid-Related Disorders; Pri | 2019 |
High prevalence but low awareness of hepatitis C virus infection among heroin users who received methadone maintenance therapy in Taiwan.
Topics: Adult; Analgesics, Opioid; Criminals; Female; Health Knowledge, Attitudes, Practice; Hepatitis B; He | 2013 |
Scaling up opioid dependence treatment in low- and middle-income settings.
Topics: Cost-Benefit Analysis; Counseling; Developing Countries; Global Health; Harm Reduction; Hepatitis C; | 2013 |
HIV and hepatitis C virus testing delays at methadone clinics in Guangdong Province, China.
Topics: Adult; Asian People; China; Female; Hepatitis C; HIV Infections; Humans; Male; Mass Screening; Metha | 2013 |
Hepatitis C virus infection is independently associated with depression among methadone maintenance treatment heroin users in China.
Topics: Adult; China; Comorbidity; Depression; Female; Hepatitis C; Humans; Male; Methadone; Middle Aged; Op | 2013 |
Hepatitis C virus infection influences the S-methadone metabolite plasma concentration.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Cell Line, Transformed; Cytochrome P-450 CYP2B6; Demography; D | 2013 |
HIV and hepatitis C virus test uptake at methadone clinics in Southern China: opportunities for expanding detection of bloodborne infections.
Topics: Adult; China; Cross-Sectional Studies; Drug Users; Female; Hepatitis C; HIV Infections; Humans; Male | 2013 |
High prevalence of HIV, HCV and tuberculosis and associated risk behaviours among new entrants of methadone maintenance treatment clinics in Guangdong Province, China.
Topics: Adult; Analgesics, Opioid; China; Coinfection; Comorbidity; Female; Hepatitis C; HIV Infections; Hum | 2013 |
[Study on the incidence and risk factors of HCV infection among heroin addicts who were on methadone maintenance treatment in Dehong prefecture,Yunnan province].
Topics: Adolescent; Adult; Aged; China; Cohort Studies; Drug Users; Female; Hepatitis C; Humans; Incidence; | 2013 |
Long-term effects of methadone maintenance treatment with different psychosocial intervention models.
Topics: Adult; China; Counseling; Female; Follow-Up Studies; Hepatitis C; HIV; HIV Infections; Humans; Male; | 2014 |
Absence of neurocognitive impairment in a large Chinese sample of HCV-infected injection drug users receiving methadone treatment.
Topics: Adult; Asian People; Cognition Disorders; Female; Hepatitis C; Humans; Male; Methadone; Neuropsychol | 2014 |
Incidence of hepatitis C infection among prisoners by routine laboratory values during a 20-year period.
Topics: Adult; Analgesics, Opioid; Coinfection; Follow-Up Studies; Hepacivirus; Hepatitis C; Hepatitis C Ant | 2014 |
The geographic distribution patterns of HIV-, HCV- and co-infections among drug users in a national methadone maintenance treatment program in Southwest China.
Topics: Adult; China; Coinfection; Drug Users; Female; Geography, Medical; Hepatitis C; HIV Infections; Huma | 2014 |
Trends in substance abuse and infectious disease over 20 years in a large methadone maintenance treatment (MMT) clinic in Israel.
Topics: Adult; Female; Hepatitis C; HIV Seroprevalence; Humans; Israel; Male; Methadone; Opiate Substitution | 2014 |
Evaluation of state opioid substitution treatment program in Georgia.
Topics: Adult; Aged; Alcoholism; Buprenorphine; Female; Georgia (Republic); Government Programs; Hepatitis B | 2014 |
Substance use and hepatitis C: an ecological momentary assessment study.
Topics: Adult; Affect; Antiviral Agents; Cocaine-Related Disorders; Craving; Female; Hepatitis C; Heroin Dep | 2014 |
The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users.
Topics: Adult; Alcoholism; British Columbia; Cohort Studies; Female; Hepatitis C; Humans; Illicit Drugs; Mal | 2014 |
Hepatitis B and C prevalence among heroin addicts in methadone maintenance treatment (MMT) and not in MMT in Pereira, Colombia.
Topics: Adult; Colombia; Female; Hepatitis B; Hepatitis C; Heroin Dependence; Humans; Male; Methadone; Preva | 2014 |
Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
Topics: Adolescent; Adult; Buprenorphine; Cohort Studies; Disease Transmission, Infectious; Drug Users; Fema | 2014 |
Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China.
Topics: Adult; China; Cross-Sectional Studies; Female; Hepatitis C; Humans; Male; Methadone; Opiate Substitu | 2015 |
Who uses methadone services in China? Monitoring the world's largest methadone programme.
Topics: Adult; Analgesics, Opioid; China; Cohort Studies; Database Management Systems; Drug Users; Female; H | 2015 |
A model for treating HCV hepatitis in patients receiving methadone maintenance therapy.
Topics: Adult; Antiviral Agents; Comorbidity; Hepatitis C; Humans; Interferon-alpha; Methadone; Narcotics; O | 2014 |
Commentary on Zhou et al. (2015): Research on methadone maintenance treatment (MMT) as prevention for HCV infection--MMT is not a single variable.
Topics: Hepatitis C; Humans; Methadone; Narcotics; Opiate Substitution Treatment | 2015 |
Factors associated with methadone treatment duration: a Cox regression analysis.
Topics: Adult; Demography; Female; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Male; Methadone; | 2015 |
Chemokine IP-10 is correlated with cardiac responses and status of infection with HIV and HCV in methadone maintenance patients.
Topics: Adult; Chemokine CXCL10; Chemokines; Electrocardiography; Female; Hepatitis C; Heroin Dependence; HI | 2015 |
Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.
Topics: Adult; Buprenorphine; Case-Control Studies; Coinfection; Female; Hepatitis C; HIV Infections; Humans | 2015 |
Simeprevir-induced severe withdrawal syndrome in an HIV/HCV coinfected patient on long-term maintenance methadone therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Drug Interactions; Hepatitis C | 2015 |
"Hepatitis C treatment turned me around:" Psychological and behavioral transformation related to hepatitis C treatment.
Topics: Adult; Analgesics, Opioid; Drug Users; Female; Hepatitis C; Humans; Male; Methadone; Middle Aged; Op | 2015 |
Trends and risk factors for HIV, HCV and syphilis seroconversion among drug users in a methadone maintenance treatment programme in China: a 7-year retrospective cohort study.
Topics: Adult; Analgesics, Opioid; China; Drug Users; Female; Follow-Up Studies; Hepatitis C; HIV Infections | 2015 |
[Prevalence of HIV and HCV infections in patients receiving methadone maintenance treatment in Kaiyuan, Yunnan].
Topics: China; Coinfection; Drug Users; Hepatitis C; HIV Infections; Humans; Methadone; Opiate Substitution | 2015 |
Baseline HCV Antibody Prevalence and Risk Factors among Drug Users in China's National Methadone Maintenance Treatment Program.
Topics: Adolescent; Adult; China; Drug Users; Female; Geography; Hepatitis C; Hepatitis C Antibodies; Humans | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
Integrated respondent-driven sampling and peer support for persons who inject drugs in Haiphong, Vietnam: a case study with implications for interventions.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Female; Health Services Accessibili | 2016 |
The physical health of people who inject drugs: complexities, challenges, and continuity.
Topics: Antiviral Agents; Delivery of Health Care; Disease Transmission, Infectious; General Practice; Healt | 2016 |
[Tracing hepatitis C virus transmission by using high-throughput sequencing technique].
Topics: Adult; Antibodies, Viral; China; Contact Tracing; Genetic Variation; Genotype; Hepacivirus; Hepatiti | 2016 |
[HCV infection status and related risk factors in drug users under HIV sentinel surveillance in Henan province, 2011-2015].
Topics: China; Cross-Sectional Studies; Drug Users; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Hum | 2016 |
Hepatitis C Treatment Uptake among Patients Who Have Received Opioid Substitution Treatment: A Population-Based Study.
Topics: Adult; Antipsychotic Agents; Antiviral Agents; Benzodiazepines; Buprenorphine, Naloxone Drug Combina | 2016 |
Population dynamics of hepatitis C virus subtypes in injecting drug users on methadone maintenance treatment in China associated with economic and health reform.
Topics: Adult; Analgesics, Opioid; China; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Male; Methadon | 2017 |
Hepatitis C in a Mobile Low-Threshold Methadone Program.
Topics: Adult; Aged; Alcohol-Related Disorders; Coinfection; Comorbidity; Cross-Sectional Studies; Drug User | 2017 |
Examination of the Hepatitis C Virus care continuum among individuals with an opioid use disorder in substance use treatment.
Topics: Adult; Buprenorphine; Continuity of Patient Care; Female; Hepatitis C; Humans; Male; Methadone; Midd | 2017 |
Assessment of alcohol use among methadone maintenance patients by direct ethanol metabolites and self-reports.
Topics: Adult; Alcohol Drinking; Biomarkers; Esters; Ethanol; Female; Glucuronates; Hair; Hepatitis C; Human | 2008 |
Drug treatment clients' readiness for hepatitis C treatment: implications for expanding treatment services in drug and alcohol settings.
Topics: Adolescent; Adult; Female; Health Care Surveys; Health Knowledge, Attitudes, Practice; Hepatitis C; | 2008 |
Implementation of drug substitution therapy in Georgia.
Topics: Georgia (Republic); Harm Reduction; Hepatitis C; HIV Infections; Humans; Methadone; Narcotics; Psych | 2008 |
Alcohol use reduction program in methadone maintained individuals with hepatitis C virus infection.
Topics: Adult; Aged; Alcoholism; Analgesics, Opioid; Attitude of Health Personnel; Delivery of Health Care; | 2008 |
Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection.
Topics: Adult; Depression; Ethnicity; Health Status; Hepatitis C; Humans; Mental Health; Methadone; Middle A | 2009 |
Access to sterile injecting equipment is more important than awareness of HCV status for injection risk behaviors among drug users.
Topics: Adult; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Hepatitis C; Humans; | 2009 |
Treatment of hepatitis C infection for current or former substance abusers in a community setting.
Topics: Adult; Antiviral Agents; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Me | 2009 |
Prevalence of problem alcohol use among patients attending primary care for methadone treatment.
Topics: Adult; Alcoholism; Analgesics, Opioid; Cross-Sectional Studies; Female; Hepatitis C; Heroin Dependen | 2009 |
[A study of mix-infections with different genotypes of hepatitis C virus in patients from a methadone maintenance clinic in Wuhan].
Topics: Adult; China; Genes, Viral; Genotype; Hepacivirus; Hepatitis C; Humans; Methadone; Middle Aged; Opio | 2009 |
Screening for hepatitis C virus infection in methadone-maintained mothers and their infants.
Topics: Adult; Analgesics, Opioid; Female; Hepatitis C; Humans; Infant; Infant, Newborn; Methadone; Neonatal | 2009 |
Knowledge about Hepatitis-C among methadone maintenance treatment patients in Israel.
Topics: Adult; Drug Users; Female; Health Knowledge, Attitudes, Practice; Hepatitis C; Humans; Israel; Male; | 2010 |
Uptake and delivery of hepatitis C treatment in opiate substitution treatment: perceptions of clients and health professionals.
Topics: Adolescent; Adult; Attitude of Health Personnel; Delivery of Health Care; Female; Health Knowledge, | 2010 |
Incidence and risk for acute hepatitis C infection during imprisonment in Australia.
Topics: Adult; Antibodies, Viral; Australia; Enzyme-Linked Immunosorbent Assay; Female; Health Behavior; Hep | 2010 |
Methadone maintenance patients' knowledge, attitudes, beliefs, and experiences concerning treatment for hepatitis C virus infection.
Topics: Adult; Female; Health Knowledge, Attitudes, Practice; Hepatitis C; Humans; Male; Methadone; Patient | 2010 |
Select barriers to harm-reduction services for IDUs in eastern Europe.
Topics: Age Factors; Confidentiality; Europe, Eastern; Fees and Charges; Harm Reduction; Health Services Acc | 2009 |
Improvement in hepatopulmonary syndrome after methadone withdrawal: a case report with implications for disease mechanism.
Topics: Hepatitis C; Hepatopulmonary Syndrome; Humans; Liver Cirrhosis; Male; Methadone; Middle Aged; Narcot | 2010 |
Can Hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere.
Topics: Antiviral Agents; Australia; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Methadone; M | 2011 |
Scaling up the national methadone maintenance treatment program in China: achievements and challenges.
Topics: China; Crime; Health Education; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Methadone; N | 2010 |
Integrated internist - addiction medicine - hepatology model for hepatitis C management for individuals on methadone maintenance.
Topics: Adult; Antiviral Agents; Behavior, Addictive; Disease Management; Female; Genotype; Hepacivirus; Hep | 2012 |
Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy.
Topics: Adult; Antiviral Agents; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV | 2011 |
The establishment of a methadone treatment clinic for women in Tehran, Iran.
Topics: Adolescent; Adult; Ambulatory Care Facilities; Analgesics, Opioid; Female; Harm Reduction; Hepatitis | 2011 |
Clinical characteristics and risk behavior as a function of HIV status among heroin users enrolled in methadone treatment in northern Taiwan.
Topics: Adult; Dose-Response Relationship, Drug; Female; Hepatitis C; Heroin Dependence; HIV Seronegativity; | 2011 |
The effects of widespread methadone treatment on the molecular epidemiology of hepatitis C virus infection among injection drug users in Hong Kong.
Topics: Adult; Age Factors; Cluster Analysis; Drug Administration Schedule; Drug Users; Female; Genotype; He | 2011 |
A 25-year follow-up of patients admitted to methadone treatment for the first time: mortality and gender differences.
Topics: Adult; Aged, 80 and over; Female; Follow-Up Studies; Hepatitis B; Hepatitis C; Heroin Dependence; HI | 2011 |
Low risk for hepatitis C seroconversion in methadone maintenance treatment.
Topics: Adult; Age Distribution; Benzodiazepines; Cohort Studies; Comorbidity; Female; Follow-Up Studies; He | 2011 |
Characteristics of Iranian women seeking drug treatment.
Topics: Adolescent; Adult; Analysis of Variance; Female; Health Status; Hepatitis C; HIV Infections; Humans; | 2011 |
Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: Association between methadone use and bone loss.
Topics: Adult; Age Factors; Body Mass Index; Bone Density; Bone Resorption; Female; Hepatitis C; HIV Infecti | 2011 |
Hepatitis B virus and hepatitis C virus services offered by substance abuse treatment programs in the United States.
Topics: Cross-Sectional Studies; Guidelines as Topic; Health Services; Health Services Accessibility; Hepati | 2012 |
Attitudes of methadone program staff toward provision of harm-reduction and other services.
Topics: Adult; AIDS Serodiagnosis; Attitude of Health Personnel; Data Collection; Delivery of Health Care; F | 2011 |
The politics of place(ment): problematising the provision of hepatitis C treatment within opiate substitution clinics.
Topics: Ambulatory Care Facilities; Antiviral Agents; Australia; Cross-Sectional Studies; Female; Health Car | 2012 |
Hepatitis C among methadone maintenance treatment patients in Shanghai and Kunming, China.
Topics: Adult; Analysis of Variance; China; Female; Health Knowledge, Attitudes, Practice; Hepacivirus; Hepa | 2012 |
A pilot training program for a motivational enhancement approach to hepatitis C virus treatment among individuals in Israeli methadone treatment centers.
Topics: Counseling; Hepacivirus; Hepatitis C; Humans; Israel; Methadone; Motivation; Patient Acceptance of H | 2012 |
Hepatitis C knowledge and alcohol consumption among patients receiving methadone maintenance treatment in Shanghai, China.
Topics: Adult; Alcohol Drinking; Antiviral Agents; China; Cross-Sectional Studies; Female; Health Knowledge, | 2012 |
Assessment of methadone clinic staff attitudes toward hepatitis C evaluation and treatment.
Topics: Adolescent; Adult; Attitude of Health Personnel; Educational Status; Female; Hepatitis C; Humans; Ma | 2013 |
Survey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Drug Interactions; Female; | 2012 |
Finasteride and methadone use and risk of advanced hepatitis C related liver disease.
Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Cross-Sectional Studies; Finasteride; Hepatitis C; Humans | 2012 |
HIV infection risk among injection drug users in a methadone maintenance treatment program, Taipei, Taiwan 2007-2010.
Topics: Adult; AIDS Serodiagnosis; Cross-Sectional Studies; Female; Hepatitis C; HIV Infections; HIV Seroneg | 2012 |
Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland.
Topics: Adolescent; Adult; Cross-Sectional Studies; Female; Harm Reduction; Hepatitis C; Humans; Incidence; | 2012 |
Methadone maintenance treatment in China: perceived challenges from the perspectives of service providers and patients.
Topics: Adult; Attitude of Health Personnel; Attitude to Health; China; Female; Focus Groups; Health Service | 2013 |
HCV and HIV infection among heroin addicts in methadone maintenance treatment (MMT) and not in MMT in Changsha and Wuhan, China.
Topics: Adult; China; Female; Hepatitis C; Heroin Dependence; HIV Infections; Humans; Male; Methadone; Middl | 2012 |
High prevalence of HIV, syphilis and HCV, and low methadone maintenance treatment in a migrant population in Beijing.
Topics: Adult; China; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Health Services Acc | 2012 |
Unprotected sex among HIV-positive treatment-seeking opioid-dependent adults in China: a cross-sectional study.
Topics: Adult; China; Cross-Sectional Studies; Female; Government Programs; Health Behavior; Hepatitis C; HI | 2012 |
Methadone diversion as a protective strategy: the harm reduction potential of 'generous constraints'.
Topics: Administration, Oral; Analgesics, Opioid; Attitude of Health Personnel; Drug Administration Schedule | 2013 |
Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan.
Topics: Adult; Coinfection; Cross-Sectional Studies; Dose-Response Relationship, Drug; Female; Hepatitis C; | 2012 |
Hepatitis C virus and human immunodeficiency virus-1 co-infection in former heroin addicts in methadone maintenance treatment.
Topics: Adult; Comorbidity; Hepatitis C; HIV Infections; HIV-1; Humans; Methadone; New York; Substance Abuse | 2002 |
Methadone maintenance expands inside federal prisons.
Topics: Analgesics, Opioid; Canada; Hepatitis C; HIV Infections; Human Rights; Humans; Methadone; Opioid-Rel | 2002 |
What's new for injection drug users with HIV infection?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Disease Outbreaks; Drug Interactions; Health | 2003 |
[Prevalence of infection by HIV and hepatitis C virus in a cohort of patients on methadone treatment].
Topics: Adult; Analgesics, Opioid; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Male; Methad | 2003 |
[Prevalence of serological markers of viral hepatitis B and hepatitis C in drug-dependent individuals treated at the Drop Methadone Center in Prague].
Topics: Adult; Czech Republic; Female; Hepatitis A; Hepatitis B; Hepatitis C; Humans; Male; Methadone; Middl | 2003 |
Gaps in the drug-free and methadone treatment program response to Hepatitis C.
Topics: Health Care Surveys; Health Services Accessibility; Hepatitis C; Humans; Methadone; Opioid-Related D | 2003 |
Finding a vein or obtaining consent: a qualitative study of hepatitis C testing in GP methadone clinics.
Topics: Attitude of Health Personnel; Coercion; Hepatitis C; Humans; Informed Consent; Interviews as Topic; | 2003 |
Liver transplantation for methadone-maintained opiate dependents: making the case for cautious optimism.
Topics: Contraindications; Female; Hepatitis C; Humans; Liver Transplantation; Male; Methadone; Narcotics; O | 2003 |
A matched comparison study of medical and psychiatric complications and anesthesia and analgesia requirements in methadone-maintained liver transplant recipients.
Topics: Adult; Analgesics, Opioid; Comorbidity; Female; Hepatitis C; Humans; Liver Cirrhosis; Liver Transpla | 2004 |
A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.
Topics: Health Care Surveys; Health Services Accessibility; Health Services Research; Hepatitis C; Hepatitis | 2004 |
The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units.
Topics: Analgesics, Opioid; Health Care Surveys; Health Education; Hepatitis C; Humans; Methadone; Program E | 2004 |
What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand?
Topics: Adult; Antiviral Agents; Cost-Benefit Analysis; Female; Hepatitis C; Humans; Male; Markov Chains; Me | 2004 |
Prevalence of HIV, hepatitis B, C and G virus infections among injecting drug users on methadone maintenance treatment in Maribor.
Topics: Adult; Age Factors; Cross-Sectional Studies; Female; Flaviviridae Infections; GB virus C; Hepatitis | 2004 |
[The profile of drug addicts attending the Sainte Marguerite University Hospital in Marseille analysis of the active file from 1996 to 2001].
Topics: Adult; Age Distribution; Buprenorphine; Cohort Studies; Drug Overdose; Female; France; Hallucinogens | 2004 |
Outpatient drug treatment program directors' hepatitis C-related beliefs and their relationship to the provision of HCV services.
Topics: Adult; Ambulatory Care; Attitude of Health Personnel; Combined Modality Therapy; Comorbidity; Cultur | 2004 |
Hepatitis C virus incidence among injecting drug users on opioid replacement therapy.
Topics: Adult; Analgesics, Opioid; Buprenorphine; Cohort Studies; Drug Therapy, Combination; Female; Hepatit | 2004 |
Treating hepatitis C virus infection in active substance users.
Topics: Female; Hepatitis C; Humans; Male; Mental Disorders; Methadone; Middle Aged; Substance Abuse, Intrav | 2005 |
Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
Topics: Adult; Aged; Delivery of Health Care, Integrated; Eligibility Determination; Female; Hepatitis C; Hu | 2005 |
Knowledge of and interest in hepatitis C treatment at a methadone clinic.
Topics: Adult; Comorbidity; Cross-Sectional Studies; Female; Health Knowledge, Attitudes, Practice; Health S | 2005 |
Experience of hepatitis C among current or former heroin users attending general practice.
Topics: Adolescent; Adult; Alcohol Drinking; Comorbidity; Family Practice; Female; Health Knowledge, Attitud | 2005 |
Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
Topics: Adult; Australia; Disease Transmission, Infectious; Female; Follow-Up Studies; Hepacivirus; Hepatiti | 2005 |
Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study.
Topics: Buprenorphine; Cohort Studies; Comorbidity; Cross-Sectional Studies; Dose-Response Relationship, Dru | 2005 |
Feasibility and outcome of HCV treatment in a Canadian federal prison population.
Topics: Adult; British Columbia; DNA, Viral; Drug Combinations; Feasibility Studies; Federal Government; Gen | 2005 |
The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone.
Topics: Delivery of Health Care; Female; Hepatitis C; Heroin Dependence; Humans; Male; Mental Disorders; Met | 2005 |
Linkage with methadone treatment upon release from incarceration: a promising opportunity.
Topics: Crime; Health Services Needs and Demand; Hepatitis B; Hepatitis C; HIV Infections; Humans; Long-Term | 2005 |
Dental management of patients taking methadone.
Topics: Dental Care; Dental Caries; Hepatitis C; HIV Infections; Humans; Methadone; Narcotics; Opioid-Relate | 2005 |
[Quality assurance in patient addiction treated with drug substitution].
Topics: Antiviral Agents; Buprenorphine; Comorbidity; Drug Information Services; Drug Interactions; Drug The | 2005 |
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Topics: Adult; Anti-Retroviral Agents; British Columbia; Cohort Studies; Comorbidity; Demography; Female; Fo | 2006 |
Safety, efficacy, and tolerability of nelfinavir-containing antiretroviral therapy for patients coinfected with HIV and hepatitis C undergoing methadone maintenance.
Topics: Adult; Anti-HIV Agents; Female; Hepatitis C; HIV Infections; Humans; Male; Methadone; Middle Aged; N | 2006 |
HIV sexual risk behaviors among injection drug users in Shanghai.
Topics: Adult; Catchment Area, Health; China; Cross-Sectional Studies; Demography; Female; Hepatitis B; Hepa | 2006 |
Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic.
Topics: Ambulatory Care; Female; Hepatitis C; HIV Infections; Humans; Israel; Male; Mental Disorders; Methad | 2006 |
[Health related quality of life among HIV-HCV co-infected patients].
Topics: Adult; Anti-Retroviral Agents; Buprenorphine; Cohort Studies; Counseling; Data Interpretation, Stati | 2006 |
[Pharmacy syringe exchange program for injection drug users].
Topics: Adult; Data Collection; France; Hepatitis C; Humans; Methadone; Middle Aged; Narcotics; Needle Shari | 2006 |
Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs.
Topics: Ambulatory Care; Attitude of Health Personnel; Data Interpretation, Statistical; Hepatitis C; Humans | 2006 |
Liver transplant and hepatitis C in methadone maintenance therapy: a case report.
Topics: Adult; Analgesics, Opioid; Antiviral Agents; Drug Therapy, Combination; Hepatitis C; Humans; Interfe | 2007 |
Zopiclone misuse: an update from Dublin.
Topics: Adult; Azabicyclo Compounds; Benzodiazepines; Comorbidity; Cross-Sectional Studies; Female; Hepatiti | 2007 |
Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Topics: Adult; Aged; Family Practice; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Illicit Drug | 2007 |
Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
Topics: Analgesics, Opioid; Harm Reduction; Health Promotion; Hepacivirus; Hepatitis C; Humans; Methadone; N | 2007 |
Body composition, gender, and illicit drug use in an urban cohort.
Topics: Baltimore; Black People; Body Composition; Body Mass Index; Cocaine-Related Disorders; Comorbidity; | 2007 |
A longitudinal investigation into excess risk for blood-borne infection among young injection drug users (IUDs).
Topics: Adult; Age Factors; Amphetamine-Related Disorders; British Columbia; Cocaine-Related Disorders; Comm | 2007 |
Case study: accessible primary health care--a foundation to improve health outcomes for people who inject drugs.
Topics: Anti-HIV Agents; Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Methadone; Narc | 2007 |
Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users.
Topics: Adult; Cohort Studies; Female; Harm Reduction; Hepatitis C; HIV Infections; Humans; Incidence; Male; | 2007 |
Hepatitis C treatment, subcutaneous naltrexone implants, and methadone maintenance treatment.
Topics: Antiviral Agents; Drug Implants; Hepatitis C; Humans; Methadone; Morphine Dependence; Naltrexone; Na | 2007 |
Rethinking approaches to risk reduction for injection drug users: differences in drug type affect risk for HIV and hepatitis C virus infection through drug-injecting networks.
Topics: Adolescent; Adult; Age of Onset; Cocaine-Related Disorders; Cross-Sectional Studies; Female; Hepatit | 2007 |
Methadone maintenance treatment (MMT) in general practice or in specialized centers: profile of patients in the Swiss Canton of Vaud.
Topics: Adult; AIDS Serodiagnosis; Antipsychotic Agents; Cocaine-Related Disorders; Cross-Sectional Studies; | 2007 |
Hepatitis C and human immunodeficiency virus risk behaviors in polydrug users on methadone maintenance.
Topics: Adult; Female; Hepatitis C; HIV Infections; Humans; Male; Methadone; Risk-Taking; Sexual Behavior; S | 2008 |
High prevalence of HCV in a cohort of injectors on methadone substitution treatment.
Topics: Cohort Studies; Female; Hepatitis C; Hepatitis C Antibodies; Hong Kong; Humans; Male; Methadone; Mid | 2008 |
Buprenorphine injection in Melbourne, Australia--an update.
Topics: Australia; Buprenorphine; Catchment Area, Health; Cohort Studies; Cross-Sectional Studies; Harm Redu | 2008 |
Hepatitis C seroprevalence amongst injecting drug users attending a methadone programme.
Topics: Adult; Blood Donors; Female; Hepatitis C; Hepatitis C Antibodies; Humans; Male; Methadone; Narcotics | 1995 |
Hepatitis C virus infection among a cohort of Victorian injecting drug users.
Topics: Adult; Cohort Studies; DNA, Viral; Female; Hepacivirus; Hepatitis Antibodies; Hepatitis C; Hepatitis | 1993 |
A longitudinal study on the incidence and transmission patterns of HIV, HBV and HCV infection among drug users in Amsterdam.
Topics: Adult; Comorbidity; Condoms; Female; Germany; Hepatitis B; Hepatitis C; HIV Infections; Homosexualit | 1993 |
Incidence and prevalence of hepatitis C among clients of a Brisbane methadone clinic: factors influencing hepatitis C serostatus.
Topics: Adolescent; Adult; Female; Hepatitis C; Humans; Incidence; Male; Methadone; Middle Aged; Prevalence; | 1997 |
Methadone maintenance and hepatitis C virus infection among injecting drug users.
Topics: Adult; Female; Hepatitis C; Humans; Male; Methadone; Middle Aged; Narcotics; Substance Abuse, Intrav | 1997 |
Truncated recurrent event survival models for methadone data.
Topics: Biometry; Female; Hepatitis C; Heroin Dependence; HIV Seropositivity; Humans; Likelihood Functions; | 1997 |
Addiction treatment: promoting a medical approach to substance use.
Topics: Blood-Borne Pathogens; Delivery of Health Care, Integrated; Financial Support; Health Promotion; Hea | 1998 |
Prevalence and incidence rate of HIV, hepatitis B and C among drug users on methadone maintenance treatment in Geneva between 1988 and 1995.
Topics: Cohort Studies; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Incidence; Male; Methadone | 1998 |
Correlates of benzodiazepine abuse in methadone maintenance treatment. A 1 year prospective study in an Israeli clinic.
Topics: Adult; Benzodiazepines; Female; Hepatitis C; HIV Infections; Humans; Israel; Male; Methadone; Narcot | 1999 |
[Axillary plexus catheter block in accidental intra-arterial levomethadone HCl injection in an HIV-positive, hepatitis B and C active drug dependent patient].
Topics: Adult; Amides; Anesthetics, Local; Arm; Axillary Artery; Blood Flow Velocity; Brachial Plexus; Cathe | 2000 |
Methadone treatment and HIV and hepatitis B and C risk reduction among injectors in the Seattle area.
Topics: Adult; Cohort Studies; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Incidence; Male; Me | 2000 |
Dilated bile duct in patients receiving narcotic substitution: an early report.
Topics: Adult; Bile Duct Diseases; Bile Ducts; Biopsy; Buprenorphine; Common Bile Duct; Common Bile Duct Dis | 2000 |
Former addicts face barriers to treatment for HCV.
Topics: Health Services Accessibility; Hepatitis C; Humans; Methadone; Narcotics; Practice Guidelines as Top | 2001 |
Liver transplantation and opioid dependence.
Topics: Hepatitis C; Humans; Liver Transplantation; Methadone; Narcotics; Opioid-Related Disorders; Patient | 2001 |
Hepatitis C in methadone maintenance patients: prevalence and public policy implications.
Topics: Adult; Aged; Asian; California; Comorbidity; Cross-Sectional Studies; Female; Health Policy; Hepatit | 2001 |
Hepatitis C, B, D, and A: contrasting features and liver function abnormalities in heroin addicts.
Topics: Carrier State; Hepatitis A; Hepatitis B; Hepatitis C; Hepatitis D; Heroin Dependence; Humans; Liver | 2001 |
Prevalence of hepatitis B and C infection in a methadone clinic population: implications for hepatitis B vaccination.
Topics: Adult; Comorbidity; Cross-Sectional Studies; Feasibility Studies; Female; Hepatitis B; Hepatitis B V | 2001 |
A reduction in HIV positive and an increase in hepatitis C positive subjects in methadone maintenance treatments.
Topics: Cross-Sectional Studies; Hepatitis C; HIV Infections; Humans; Methadone; Narcotics; Opioid-Related D | 2001 |
HIV and hepatitis virus infections among injecting drug users in a medically controlled heroin prescription programme.
Topics: Adult; Drug Prescriptions; Female; Health Policy; Hepatitis B; Hepatitis C; Heroin; HIV Infections; | 2001 |
Irish prison guards call for expansion of methadone access.
Topics: Health Services Accessibility; Hepatitis C; HIV Infections; Humans; Ireland; Methadone; Prisons | 2001 |
Treating hepatitis C in methadone maintenance patients: an interim analysis.
Topics: Adult; Aged; Chi-Square Distribution; Drug Therapy, Combination; Female; Hepatitis C; Humans; Interf | 2002 |
Incidence of hepatitis C, hepatitis B and HIV infections among drug users in a methadone-maintenance programme.
Topics: Hepatitis B; Hepatitis C; HIV Infections; Humans; Incidence; Methadone; Substance Abuse, Intravenous | 1992 |